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ABSTRACT
Schizophrenia is a devastating mental disorder influencing functions of the central
nervous system. Olanzapine, an atypical antipsychotic drug, is extremely efficient in
treating both the positive and negative symptoms, as well as the cognitive deficits of
schizophrenia. However, it induces some serious side effects, such as body weight
gain/obesity, hormonal dysfunction and other metabolic disorders. Since the
antagonistic affinities to histamine H1 receptors of antipsychotic drugs are thought to
be one of the main indicators of antipsychotic-induced weight gain/obesity, it is
proposed that a histamine H1 receptor agonist may have potential to reduce
antipsychotic-induced weight gain side effects.

This project aimed to investigate whether a combined treatment of betahistine (a
histamine H1 receptor agonist and H3 receptor antagonist) with olanzapine could
improve the body weight/obesity side effects induced by olanzapine in a rat model.
Forty-nine female Sprague Dawley rats were divided into four groups and fed orally
with olanzapine (3 mg/kg/day) and/or betahistine (8 mg/kg/day), or vehicle for two
weeks. Body weight, food intake, water intake and locomotor activity were measured.
An intra-peritoneal glucose challenge test was conducted. Blood samples were taken
for measuring appetite hormones including plasma insulin and PYY. White and
brown fat tissue was collected and weighed. Brain tissue was obtained for histamine
H1 receptor binding experiments in key regions of the brain involved in food intake
and body weight regulation.
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Rats treated solely with olanzapine exhibited significant body weight gain and
increased food intake. However, sole betahistine treatment had no effect on weight
gain and food intake. Co-treatment of olanzapine with betahistine significantly
reduced (-33%) weight gain and feeding efficiency compared to sole olanzapine
treatment. Olanzapine treatment reduced locomotor activity and increased white fat
tissue; however betahistine had no influence on these parameters. These results
suggested that co-treatment with betahistine partially improves the body weight gain
side effect induced by olanzapine.

The hormone measurements in this project revealed that olanzapine tended to
decrease fasting plasma insulin levels, and that co-treatment of olanzapine and
betahistine can improve insulin levels. No change was detected in plasma PYY levels.

The H1 receptor binding experiments revealed a tendency for betahistine to increase
H1 receptor binding density in the ventromedial hypothalamic nucleus (VMH), and
significantly decreased H1 receptor binding density in the dorsal vagal complex
(DVC), with no significant effect in the arcuate hypothalamic nucleus (Arc). There
was no difference in H1 receptor binding in these nuclei following olanzapine
treatment, possibly due to the influence of overnight fasting.

In conclusion, the findings of this project revealed that olanzapine-induced body
weight gain could partially be reduced by co-treatment with betahistine, which
confirms our hypothesis that use of an H1 receptor agonist can improve
antipsychotic-induced weight gain/obesity side effects. These findings have
viii

important implications for clinical trials involving the use of betahistine to improve
olanzapine-induced weight gain/obesity side effects. Furthermore, the finding of this
study may aid in the development of a new treatment strategy for schizophrenia
patients.
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
1.1 Introduction
With our entry into the twenty-first century, schizophrenia remains a dynamic,
multidimensional, heterogeneous and genetically complicated disease with no
unequivocally established, contributory environmental factors. Although substantial
progress has been achieved in both diagnosis and treatment of the disorder and in
understanding the disorder’s neurobiological substrates, a full understanding of its
origins and pathogenic mechanisms remains elusive. Schizophrenia is characterised
by positive and negative symptoms, as well as cognitive deficits. Antipsychotics
have been the mainstay treatment of schizophrenia which is broadly classified as
typical and atypical antipsychotics. Typical antipsychotics can ameliorate the
positive symptoms of schizophrenia, through blockade of the D2 dopamine receptor.
However, D2 blockade induces extra-pyramidal symptoms such as tardive dyskinesia.
The newer generation (atypical antipsychotic) drugs are effective in relieving the
positive and negative symptoms, as well as cognitive deficits of schizophrenia, with
reduced risk of extra-pyramidal symptoms. However, atypical antipsychotics cause
some other side effects, such as body weight gain/obesity and other metabolic
symptoms (Nasrallah, 2008). Metabolic dysfunction is a significant issue that needs
to be addressed in both scientific and clinical research, as it may lead to further
complications such as diabetes, cardiovascular disease, non-compliance with
medication, and premature death (by 20-30 years) (Chagnon et al., 2004; Nasrallah,
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2008; Patel et al., 2009). This critical need to control antipsychotic-induced obesity
and other metabolic side effects has been addressed in this project.

1.2 Schizophrenia
1.2.1

Overview of schizophrenia

Schizophrenia is a severe, chronic and disabling psychotic disorder affecting the
function of the central nervous system, and is one of the most costly diseases to
patients and their families (Hyman, 2000). The onset of the disorder is normally
during adolescence or early adulthood (Laruelle et al., 2003). World-wide, the
prevalence of schizophrenia is approximately one in one hundred individuals
(McGrath et al., 2003). It is believed that factors such as genetics and environmental
vulnerability can affect multiple neurotransmitter systems, such as the dopaminergic,
glutamatergic and muscarinic systems, and cause schizophrenia symptoms (Lewis
and Lieberman, 2000). However, to date, the exact aetiology of schizophrenia
remains unclear.

1.2.2

Symptoms and diagnosis

The symptoms of schizophrenia are generally separated into: (1) Positive symptoms:
the presence of abnormal thoughts and behaviour, such as delusions, hallucinations,
and disorganised speech, (2) Negative symptoms: apathy, avolition and poverty of
speech, and (3) Cognitive dysfunction: deficits in memory, attention and executive
function, (Kuperberg and Heckers, 2000). Diagnosis of schizophrenia is currently
based on symptoms, history and a few other objective signs. The American
Psychiatric Association’s standardised criteria - Diagnostic and Statistical Manual of
2

Mental Disorders (version DSM-IV-TR), as well as the World Health Organisation’s
Tenth Edition of the International Statistical Classification of Diseases and Related
Health Problems (ICD-10) are widely applied to diagnose schizophrenia.

1.3 Antipsychotic drugs
In order to relieve schizophrenia symptoms, several modalities of treatment have
been used including psychotherapy, electroconvulsive therapy, neurosurgical therapy,
as well as pharmacological intervention (Johns and Thompson, 1995; Scott and
Dixon, 1995; Matthews and Eljamel, 2003). Pharmacological intervention has
remained the most effective in treating schizophrenia. Over the past 60 years, two
generations of antipsychotic drugs have been developed to treat schizophrenia and
other psychoses. Antipsychotics, although relatively effective at treating psychotic
symptoms, can also produce problematic side effects, including Parkinsonian/extrapyramidal symptoms (Goldstein et al., 2000).

1.3.1

Typical antipsychotic drugs

The first generation of antipsychotics, also called ‘typical’ or conventional
antipsychotic drugs, are used to treat psychotic disorders, such as schizophrenia and
other mental disorders (acute mania, delusional disorders), mostly by blocking
dopamine D2 receptors (Fulton and Goa, 1997; Kapur and Remington, 2001). Since
the first typical antipsychotic drug, chlorpromazine, was discovered in the 1950s,
numerous typical antipsychotic drugs have been developed and clinically applied to
treat schizophrenia, including haloperidol, fluphenazine, loxapine, molindone,
thioridazine, zuclopenthixol, prochlorperazine, perphenazine and thiothixene.
3

Typical antipsychotic drugs help to ameliorate the positive symptoms of
schizophrenia, and have little effect on the negative symptoms of schizophrenia
(Kapur and Mamo, 2003). However, the most serious problems associated with these
drugs are extra-pyramidal symptoms (EPS) such as tardive dyskinesia and akathisia,
as well as hyperprolactinemia (Purdon et al., 2001; Montejo, 2008). Over the past 40
years, drug development and refinement has continued in order to overcome these
side effects and to treat non-responsive schizophrenia patients more effectively. Thus,
a new generation of atypical antipsychotic drugs was gradually introduced, called
‘atypical’ antipsychotics.

1.3.2

Atypical antipsychotic drugs

Atypical antipsychotic drugs are also known as second generation antipsychotics,
and currently form the first line treatment for schizophrenia (Lieberman et al., 2005).
The first atypical antipsychotic drug, clozapine, was discovered in the 1950s, and
introduced into the clinic in the 1970s. Gradually, other similar atypical
antipsychotics were introduced to the market such as olanzapine, aripiprazole,
risperidone, quetiapine and amisulpride. Atypical antipsychotic drugs enhance
therapeutic actions for treating the positive and negative symptoms, as well as
cognitive deficits of schizophrenia by binding to multiple neurotransmitter receptors,
including the dopamine, histamine, muscarinic and serotonergic receptors
(Fernández-Novoa and Cacabelos, 2001; Kapur and Mamo, 2003; Matsumoto et al.,
2005). They have also been increasingly applied to other mental disorders, such as
depression, dementia and bipolar disorder (Centorrino et al., 2002; Tuunainen et al.,
2002). There is less risk of developing EPS compared to typical antipsychotic drugs,
4

and this is due to the atypical drugs having a lower affinity for fewer D2 receptors
(Kapur and Mamo, 2003). However, clinical studies have demonstrated that some
atypical antipsychotics cause other prominent side effects such as weight gain and
obesity, which may lead to medical and social consequences, such as type II diabetes,
hypertension, cardiovascular disease, gallbladder disease, osteoarthritis, sleep apnoea
and respiratory problems, and even the relapse of psychosis due to non-compliance
(Cooper et al., 2005).

1.3.3

How serious is the weight gain side effect caused by atypical
antipsychotics?

Clinical studies have indicated that patients gain 4-5 kg of weight during the first 10
weeks of treatment with some atypical antipsychotics, such as olanzapine and
clozapine, and may continue to gain weight throughout the treatment period (Allison
et al., 1999; Nasrallah, 2008). A recent CAFE (Comparison of Atypicals for FirstEpisode Psychosis) study reported that after 12 weeks of treatment, significant
weight gain (≥ 7% body weight) occurred in a large number of schizophrenia patients
treated with olanzapine (59.8%), compared to risperidone (32.5%) and quetiapine
(29.2%). Furthermore, the same investigators found that after 52 weeks of treatment,
80% percent of olanzapine-treated patients, compared to 57.6% risperidone and 50%
quetiapine-treated patients, gained ≥ 7% body weight (Patel et al., 2009) (Table 1.1).
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Table 1.1 The percentage of patients with significant weight gain (≥ 7% body
weight) after 12 and 52 weeks treatment with olanzapine, quetiapine and risperidone.
Olanzapine

Quetiapine

Risperidone

12 weeks

59.8%

32.5%

29.2%

52 weeks

88.6%

69.7%

63.3%

(Based on data from Patel et al., 2009)

It has also been demonstrated that antipsychotic-induced weight gain is the main
cause of non-compliance and discontinuation of treatment, often resulting in the
relapse of psychosis, which can induce further toxicity in the brain (Silverstone et al.,
1988; Myers and Rosen, 1999). More importantly, some of these side effects are
associated with increased morbidity and mortality, as well as reduced quality of life
(Green et al., 2000). Although the underlying mechanisms are unclear, atypical
antipsychotic drugs have been found to disrupt glucose metabolism and increase the
risk of diabetes mellitus (Starrenburg and Bogers, 2009). It is reported that the
prevalence of diabetes mellitus and obesity in schizophrenia patients is 1.5-2.0 times
higher than the general population. Atypical antipsychotic treatment has been
identified as an additional significant risk factor for metabolic complications (Boehm
et al., 2004). Atypical antipsychotics are known to decrease insulin levels following
short-term treatment, while long-term treatment may result in insulin resistance and
diabetes (Chiu et al., 2006; Haupt, 2006; Chintoh et al., 2008b). It is particularly
noted that children and adolescents are more sensitive than adults to atypical
antipsychotic-induced weight gain/obesity, and other metabolic side effects (Correll,
2008). Therefore, compared to typical antipsychotics, although atypical antipsychotic
6

drugs have made greater progress in therapeutic effect and reducing the incidence of
EPS, they cause serious body weight gain/obesity side effects, and the mechanisms
of these side effects remain largely unknown.

1.4 Progress in the neuropharmacological mechanisms of atypical
antipsychotics-induced side effects
Antipsychotics have various affinities of binding with diverse neurotransmitter
receptors, which may play a significant role in their therapeutic and side effects
(Table 1.2). They are antagonists or agonists of many neurotransmitter receptors such
as dopamine D2, serotonin 5HT2A, 5HT2C, adrenergic alpha1-2, muscarinic M3 and
histamine H1 receptors (Nelson and Richelson, 1984; Nelson et al., 1987; Asai et al.,
1994) (Table 1.2). The potency of blockade on these receptors has been utilised to
predict the likelihood of adverse effects and drug interactions in clinical practice
(Richelson, 1996). Both typical and atypical antipsychotics bind to dopamine D2
receptors and block D2 receptors in the dopamine pathways of the brain. Typical
antipsychotic drugs are characterised by their strong antagonistic effect on dopamine
receptors, particularly the dopamine D2 receptor (Nasrallah, 2008). For example,
haloperidol acts as a high-affinity antagonist for dopamine D2, D3 and D4 receptors,
which has been known to cause extra-pyramidal side effects (Burstein et al., 2005)
(Table 1.2). On the other hand, the atypical antipsychotic drugs olanzapine and
clozapine, have a lower incidence of extra-pyramidal side effects than typical
antipsychotics (e.g. chlorpromazine; haloperidol), as they are less potent antagonists
of dopamine D2 receptors (Schotte et al., 1996). Instead, they encompass a wide
range of non-dopaminergic G-protein-coupled targets, including histamine,
7

muscarinic, serotonin, glutamate and α-adrenergic receptors (Bymaster et al., 1996;
Casey, 1997; Hale, 1997; Bymaster et al., 1999; Richelson and Souder, 2000).
Several meta-analyses have revealed that antagonistic properties of histamine H1,
5HT2C and muscarinic receptors are involved in antipsychotic-induced weight
gain/obesity (Table 1.2).

Table 1.2 Weight gain and receptor binding affinities for atypical antipsychotic
drugs.
Receptor

Haloperidol

Clozapine

Olanzapine

Quetiapine

Risperidone

Aripiprazole

5-HT2C

10000

17

6.8

2502

35

22.4

5-HT2A

53

5.4

2

101

0.17

8.7

D2

4

256

34

245

6.5

0.66

H1

1800

1.2

2

11

15

29.7

M3

10000

25

105

10000

10000

4677

α1A

12

1.64

115

22

5

26

1130

142

314.1

3630

150.8

74

0.48

4.00

3.51

2.61

1.67

0.71

α2A
Weight
Gain
(kg/10wks)

The receptor affinity values were reported as Ki (nM). 5-HT2C, serotonin2C; 5-HT2A,
serotonin2A; D2, dopamine2; H1, histamine1; M3, muscarinic3. (Data adapted from
Allison et al., 1999, Kroeze et al., 2003)

The H1 receptor antagonist properties have been identified as the main predictor for
the development of antipsychotic-induced body weight gain/obesity side effects
(approximately Clozapine > Olanzapine > Risperidone > Haloperidol > Ziprasidone >
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Aripiprizole) (Kroeze et al., 2003; Matsui-Sakata et al., 2005; Correll, 2008; Lian et
al., 2010a). It is very interesting that the olanzapine-induced body weight
gain/obesity side effect can be successfully controlled by co-administration with
aripiprazole in adult schizophrenia patients, without reducing the original olanzapine
doses (Henderson et al., 2009). Aripiprazole was developed as a D2 partial-agonist,
5-HT1A partial-agonist, and also 5-HT2A antagonist (DeLeon et al., 2004). However,
aripiprazole has a low histaminergic antagonism and does not affect H1 receptor
expression, which may account for the effect of aripiprazole in reducing olanzapineinduced obesity (DeLeon et al., 2004; Han et al., 2008).

1.4.1

Neuro-regulation of food intake and body weight gain

Normally, increased energy intake or decreased energy expenditure is the main
reason for body weight gain. Body weight is adjusted via the energy homeostasis
system. The nuclei of the hypothalamus, such as the ventromedial hypothalamus
(VMH) and arcuate nucleus (Arc) as well as the dorsal vagal complex (DVC), assist
in the regulation of food intake and energy expenditure (Hillebrand et al., 2002;
Matsui-Sakata et al., 2005). There are two neuronal populations in the Arc of the
hypothalamus that release neuropeptides in response to the peripheral appetite and
adiposity signals: neurons that express appetite inhibiting cocaine- and amphetaminerelated transcript (CART) and pro-opiomelanocortin (POMC), and neurons that
express appetite stimulating agouti-related peptide (AgRP) and neuropeptide Y
(NPY). These anorexigenic (POMC, CART and CRH) and orexigenic (NPY, AgRP
and MCH) neuropeptides are involved in this complicated regulation system.
However, to date, less attention has been paid to the brainstem regulation of energy
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balance (Schwartz et al., 2000), although some recent studies have revealed the
importance of the brainstem in detecting and responding to hunger and satiety (Grill
and Kaplan, 2002).

The neurotransmitters serotonin (5HT), noradrenaline (NA), acetylcholine (ACh) and
histamine receptors have been implicated in the regulation of energy homeostasis
(Dryden et al., 1996; Park et al., 1999; Huang et al., 2006; Deng et al., 2010). In
particular, 5-HT2 and H1 receptor antagonists are well documented to increase
appetite and obesity development (Tecott et al., 1995; Deng et al., 2010). As
described in the Table 1.2, the body weight gain/obesity side effect of atypical
antipsychotic drugs is related to its histamine H1 receptor binding affinity (Masaki
and Yoshimatsu, 2006).

1.4.2

Histamine neurotransmission and atypical antipsychotic drug-induced
body weight gain/obesity

1.4.2.1 Histamine H1 receptor and body weight regulation
Histamine exerts its actions through the four histamine receptors, termed H1, H2, H3
and H4 (Masaki and Yoshimatsu, 2006). All of them are G-protein-coupled receptors
and widely expressed in the whole body, including the central nervous system,
especially in the hypothalamus, cerebral cortex and limbic system (H1 receptors),
hippocampus, amygdale and basal ganglia (H2 receptors), basal ganglia (H3
receptors), and hypothalamus and spinal cord (H4 receptors) (Arrang et al., 1983;
Lintunen et al., 1998; Brown et al., 2001; Strakhova et al., 2009; Deng et al., 2010).
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This project focused on the histamine H1 receptor, due to its involvement in
regulating food intake. The histamine H1 receptor is expressed in the central nervous
system, smooth muscle, the heart and on vascular endothelial cells. It activates
phospholipase C and the phopsphatidyl-inositol (PIP2) signalling pathways. The
histamine H1 receptor is expressed on hypothalamic neurons as well as neurons of
the dorsal vagal complex (DVC) of the brainstem (Han et al., 2008; Poole et al.,
2008), which are involved in the regulation of food intake and energy expenditure
(Yoshimatsu et al., 2002; Masaki and Yoshimatsu, 2006; Poole et al., 2008). It has
been reported that intracerebroventricular injection of the H1 receptor agonist, 2-(3trifluoromethylpehenyl)histamine (FMPH) inhibits food intake (Sakata et al., 1997),
while H1 receptor knockout mice develop an obese phenotype (Masaki et al., 2004).

1.4.2.2 Effects of atypical antipsychotics on histamine H1 receptors and body
weight gain
Antipsychotic antagonistic affinity for the H1 receptor has been significantly
correlated with increased body weight, adiposity and insulin-resistance (Erhart et al.,
1998; Wirshing et al., 1999; Kroeze et al., 2003; Meltzer et al., 2003; Matsui-Sakata
et al., 2005). High histamine H1 receptor antagonistic affinity is a predictor for the
development of antipsychotic-induced weight gain (Stahl et al., 2009), especially
short-term weight gain (Table 1.2) (Kroeze et al., 2003). A recent study in our
laboratory showed that short (1 week) and long (12 weeks) terms of olanzapine
treatment significantly reduced H1 receptor mRNA expression in the hypothalamic
arcuate nucleus (Arc) and ventromedial hypothalamic nucleus (VMH). It is
interesting that H1 receptor mRNA expression in the Arc showed a significant
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negative correlation with food intake and fat pad mass (Han et al., 2008). It is
reported that olanzapine can directly modulate histaminergic neurotransmission,
which is correlated with the regulation of feeding behaviour of rats (Davoodi et al.,
2008). Clinical evidence also indicates that the H1 receptor antagonistic property of
antipsychotic drugs may play a role in the weight-gain/obesity side effect (Kroeze et
al., 2003). Kim and colleagues (2007) found that olanzapine and clozapine activate
hypothalamic AMP-kinase via H1 receptors to increase food intake and body weight
gain (Kim et al., 2007). As previously mentioned, although evidence suggests that
the high affinity of olanzapine to H1 receptors may contribute to its weight
gain/obesity, the exact mechanism(s) by which this atypical antipsychotic drug
induces these side effects remains largely unanswered.

Figure 1.1
The possible mechanism of Histamine H1 receptor regulate of
food intake (DVC: Dorsal vagal complex). In normal conditions, histamine can
activate H1 receptors on the hypothalamic/DVC neurons, which leads to a decrease in
food intake. However, olanzapine blocks histamine H1 receptors on
hypothalamic/DVC neurons causing an increase in food intake.
12

1.5 Atypical antipsychotic drug―Olanzapine
The atypical antipsychotic drug olanzapine was selected in this project due to its
proven efficacy in ameliorating both the positive and negative symptoms of
schizophrenia, as well as the cognitive deficits of the disorder, with less EPS, but
with a high incidence of body weight gain/obesity side effect (DeLeon et al., 2004;
Tohen et al., 2005; Nasrallah, 2008; Patel et al., 2009). The Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) study found that olanzapine was the
drug with the highest compliance, compared to other typical and atypical
antipsychotics (Lieberman et al., 2005).

Like other atypical antipsychotic drugs, olanzapine is less likely to cause extrapyramidal side effects, however its most notorious side effects are weight gain and
sedation (Allison et al., 1999). Olanzapine has a higher risk of causing weight
gain/obesity than typical antipsychotics such as chlorpromazine and haloperidol, and
other atypical antipsychotics like risperidone and aripiprazole, due to its high H1
receptor affinity (Allison et al., 1999; Kroeze et al., 2003; Patel et al., 2009) (Table
1.2). It was reported that olanzapine ranks only after clozapine as having one of the
highest incidence of weight gain side effect (Allison et al., 1999; Wirshing et al.,
1999; Taylor and McAskill, 2000). Moreover, high dosage of olanzapine-treated
schizophrenia patients has been shown to induce higher weight gain than clozapine
after one year of treatment (Zipursky et al., 2005). Therefore, it is critical to
determine the mechanism of olanzapine-induced body weight gain and whether the
H1 receptor agonist could relieve this side effect.
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In addition, among the various antipsychotic drugs, olanzapine is one of the atypical
antipsychotics with the greatest risk of inducing disturbances in glucose regulation
and elevated plasma lipid levels, which together indicate the presence of insulin
resistance and/or metabolic disturbance in humans (Allison et al., 1999; Zipursky et
al., 2005; Haupt, 2006; Iqbal and Thomas, 2007). Iqbal and colleagues reported that
olanzapine-treated patients have the highest incidence of diabetes (0.91%) compared
to patients treated with other atypical antipsychotic drugs (Iqbal and Thomas, 2007).

These results are crucial for understanding the higher risk of olanzapine in producing
hyperglycaemia and diabetes in humans.

1.6 Betahistine
The key issue is how to control the antipsychotic-induced body weight gain side
effect. Betahistine (C8H12N2) is readily available and has been used to treat more
than 100 million patients suffering from vertigo and dizziness in Canada and Europe
since the 1970s (Tighilet et al., 2007). Recently, it has also been used as an antiobesity drug in Europe. Betahistine acts as a modulator of the histaminergic system
and has both H1-agonistic and H3-antagonistic activity in the brain (Yoshida et al.,
2000; Fossati et al., 2001), with a higher affinity for the H3 receptor than the H1
(Lecklin

et

al.,

1998).

The

selective

H1

receptor

agonist,

2-(3-

trifluoromethylphenyl)histamine (FMPH), is unable to cross the blood brain barrier
(Malmberg-Aiello et al., 1998), and there is no other highly selective and orally
deliverable H1 agonist on the market. However, the combined histaminergic H1/H3
action of betahistine can reduce satiety and the desire to eat fatty foods (Szelag et al.,
2001). In addition, a small clinical trial found that betahistine was able to reduce
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olanzapine-induced weight gain (Poyurovsky et al., 2005). Furthermore, betahistine
was well tolerated and did not change the therapeutic effect of olanzapine
(Poyurovsky et al., 2005). Therefore, in this study, we investigated the effects of
betahistine on its ability to attenuate the body weight gain side effect induced by
olanzapine.

1.7 Hormonal regulation of food intake and body weight gain and
the effect of atypical antipsychotics
Energy homeostasis and body weight are regulated through an interaction between
the central nervous system and peripheral appetite signals such as insulin, peptide
YY (PYY), leptin and ghrelin (Stanley et al., 2005; Esen-Danaci et al., 2008). This
study was focused on insulin and PYY. These hormones stimulate POMC/CART
neurons (catabolic pathway) and inhibit NPY/AGRP neurons (anabolic pathway)
thus reducing food intake and increase energy expenditure. This mechanism works
quite well to address the regulation of energy homeostasis and body weight control.
It is reported that atypical antipsychotic drugs, such as olanzapine, could influence
the levels of insulin and PYY. To our knowledge, no research has been conducted to
determine the effect of betahistine on correcting the abnormal, olanzapine-induced
hormone levels.

The pancreatic hormone insulin is positively correlated with long-term energy
homeostasis (Woods, 1974). Some studies reported that acute high doses of
olanzapine administration had no significant influence on insulin levels, while others
showed decreased plasma insulin levels (Chintoh et al., 2008a; Savoy et al., 2010). In
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contrast, enhanced insulin levels were found in a chronic olanzapine administration
experiment (Perez-Iglesias et al., 2008). Furthermore, another study demonstrated
insulin resistance, indicating a direct effect on abnormal glucose level with chronic
olanzapine treatment (Chintoh et al., 2008b). Therefore, although it is known that
atypical antipsychotics influence appetite hormonal levels, the role of these
hormones in antipsychotic-induced body weight gain is still not clear.

Peripheral administration of PYY3-36 could decrease food intake and body weight
gain in rodents and humans (Batterham et al., 2002; Batterham et al., 2003). Plasma
PYY levels in obese humans are less than those in non-obese humans (le Roux et al.,
2006). A report from our group has shown that olanzapine administration
significantly reduced PYY binding density after two hours of drug treatment (Wang
and Huang, 2008). However, the exact effect of olanzapine administration on PYY is
unknown.

1.8 Animal models of olanzapine-induced weight gain/obesity
Rat models of olanzapine-induced weight gain are well established. One study
showed that olanzapine-induced weight-gain resulted at least in part from increased
food intake, reduced gross motor activity and enhanced energy efficiency in female
rats (Arjona et al., 2004). Other studies have demonstrated that chronic antipsychotic
treatment can increase body weight in female rats, but not in male rats (Baptista et al.,
1993; Baptista et al., 1998; Baptista et al., 1999; Pouzet et al., 2003; Arjona et al.,
2004). It has also been reported that olanzapine, but not clozapine, can increase body
weight in female rats only (Albaugh et al., 2006).
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The animal (rat) model of olanzapine-induced weight-gain/obesity has been
successfully established in our laboratory (Huang et al., 2006). The development of
olanzapine-induced body weight gain/obesity in female rats does show similarities
with humans in the clinic population (Figure 1.2) (Zipursky et al., 2005; Huang et al.,
2006). Figure 1.2A shows the time course for weight gain after olanzapine treatment
in human patients for two years with the greatest increase being observed during the
first 20-week period (Zipursky et al., 2005). The development of the olanzapineinduced body weight gain can be divided into three stages: firstly, early acceleration
stage; secondly, middle new equilibrium stage; and lastly, heavy weight maintenance
stage. The rat model established in our laboratory mimics the development of
olanzapine-induced body weight gain in humans. It also shows the three stages of
development, and especially, similarly to humans, there was a rapid increase in body
weight gain in the first two weeks (early acceleration stage) (Figure 1.2B) (Deng et
al., 2007; Han et al., 2008; Weston-Green et al., 2008). Therefore, this project
focused on the first two weeks of drug treatment.
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B

Figure 1.2 A: Mean weight change (kg) in olanzapine-treated schizophrenia
patients. B: Body weight gain (g) in a rodent model of olanzapine treatment
over 36 days compared to controls. (A: Adapted from The British Journal of
Psychiatry, 187, Zipursky, RB. et al., Course and predictors of weight gain in people
with first-episode psychosis treated with olanzapine or haloperidol, pp. 537-543. ©
2005, with permission from The Royal College of Psychiatrists. B: Adapted from
Behavioural Brain Research, 171, Huang X-F et al., Olanzapine differentially affects
5-HT2Aand2C receptor mRNA expression in the rat brain, pp. 355-362. © 2006, with
permission from Elsevier.)

1.9 Summary
Although the atypical antipsychotic drug olanzapine is highly effective in treating the
multiple domains of schizophrenia and is well-tolerated by patients, it has serious
side effects such as body weight-gain/obesity and metabolic side effects. Although
the exact mechanisms are still not clear, previous studies have revealed that the H1
receptor antagonism may play a key role in causing these side effects. The question
of whether betahistine, a histamine H1 receptor agonist is able to improve
olanzapine-induced side effects will be addressed in this study. As noted above,
olanzapine-induced weight gain and abnormal appetite hormonal levels have been
successfully modelled in female rats. In this project, this animal model was used to
investigate the body weight gain/obesity side effect induced by olanzapine.
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1.10 Aims
General aim:
As discussed in “Introduction and Literature Review”, olanzapine has the antagonist
property of histamine H1 receptor, and accumulated evidence suggests that the
antagonistic properties of this drug at H1 receptors may contribute to its metabolic
side effects. The aim of this study was to investigate whether a combined treatment
of H1 receptor agonist betahistine and antagonist olanzapine could improve/reduce
the olanzapine-induced body weight gain/obesity and hormonal deregulation in a rat
model.

Specific aims:
1. To determine the effects whether betahistine on improving olanzapine-induced
weight gain.
2. To examine whether olanzapine and betahistine could influence H1 receptor
binding density in the brain regions involved in food intake and body weight
regulation.
3. To study the effects of olanzapine and betahistine on appetite hormone levels and
their relationships with body weight gain and food intake.

19

1.11 Hypotheses
Since olanzapine is an H1 receptor antagonist that can increase weight gain/obesity,
we hypothesized that:
1. H1 receptor activation by an agonist could reduce body weight gain caused by
olanzapine.
2. Co-treatment of H1 receptor agonist betahistine and olanzapine may reduce the
side effects of olanzapine.
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CHAPTER 2
GENERAL METHODS
2.1 Animals and housing
Forty-nine female Sprague–Dawley rats (201-225g) were obtained from the Animal
Resources Centre (Perth, WA, Australia). In order to reduce potential stress caused
by transportation, rats were housed in pairs for 1-week prior to the start of the studies
to allow adaptation to the new environment. They were allowed ad-libitum access to
water and standard laboratory chow diet (3.9 kcal/g; 10% fat, 74% carbohydrate and
16% protein) throughout the whole experiment. During the experiment, they were
housed in individual cages under environmentally controlled conditions (22°C, light
cycle from 07:00 to 19:00 and dark cycle from 19:00 to 07:00). Rats were randomly
assigned to one control group and three treatment groups, as detailed in Table 2.1.
The cages were changed for cleaning once a week, in order to reduce interference
with animals and to provide a tidy living environment for the rats.

2.2 Experiment design
As shown in Table 2.1, this study was a 2×2 factorial design experiment to
investigate the effects of olanzapine and/or betahistine treatment on body weight gain,
food intake and other parameters (see below for details). Therefore, there were four
groups in this study, namely, control, olanzapine, betahistine and co-treatment
olanzapine with betahistine (n=12/group).

21

Table 2.1 Outline of the experiment design.
Factor 1

Non-olanzapine

Olanzapine

Non-betahistine

Control (n=12)

Olanzapine (n=13)*

Betahistine

Betahistine (n=12)

Olanzapine+Betahistine (n=12)

Factor 2

*: One rat in the olanzapine group was removed from the experiment, due to a failure
to take medication.

2.3 Drug preparation and treatment
Prior to drug treatment, rats were trained for drug treatment procedures by feeding
them cookie dough without drugs for one-week. In brief, the cookie dough
containing cornstarch (30.9%), sucrose (30.9%), gelatine (6.3%), casein (15.5%),
fibre (6.4%), minerals (8.4%) and vitamins (1.6%) was prepared. A dry powder of
the dough was made before administration. After the one-week training period,
animals were administered olanzapine (3 mg/kg/day; Eli Lilly, USA) and/or
betahistine (8 mg/kg/day; Manus Aktteva, India) orally by mixing the drugs with
cookie-dough pellets (0.3g) for two weeks (Deng et al., 2007; Han et al., 2008;
Weston-Green et al., 2008). Controls received an equivalent pellet without the drug.
The dosage of olanzapine was based on a previous experiment showing a dose
response of weight gain in our laboratory (Weston-Green et al., 2010). Olanzapine of
this dosage can significantly increase body weight gain in female rats. The dosage of
betahistine was based on a previous study in rats (Szelag et al., 2001). At this dosage,
betahistine can effectively decrease body weight gain in obese rats (Szelag et al.,
2001) (See more details in Chapter 1).
22

The 0.3g dry cookie dough containing the planned dosage of olanzapine and/or
betahistine was achieved by adding a small amount of water and given to rats by a
metal spoon 3 times per day (07:00h, 14:00h, and 22:00h; with 8±1 hour interval) for
two weeks. Rats were observed daily, making sure there was complete consumption
of the medication pellet, as well as no missing water and lab chow. Body Weight,
food intake and water intake were measured every two days. An intra-peritoneal
glucose challenge test was employed on treatment day 7 (see Chapter 3 for more
details). Open-field testing was performed on treatment day 12 (see Chapter 3 for
details). All experimental procedures were approved by the Animal Ethics
Committee, University of Wollongong, Australia (2009).

2.4 Tissue sampling
All rats underwent a drug wash-out period of 24-26 hours and 12-14 hours fasting
after the two weeks drug treatment. They were then sacrificed by carbon dioxide
asphyxiation. Blood was drawn immediately from the left ventricle of the rats, and
was centrifuged. Plasma samples were stored at -20°C for further analysis (see
Chapter 4). In order to detect the effects of drug treatments on adiposity, postmortem white adipose tissue (WAT) and sub-scapular brown adipose tissue (BAT)
were dissected and individually weighed (g) using the standard procedures
established in our laboratory (Huang et al., 2006; Han et al., 2008) (see Chapter 3).
Brain samples were removed and frozen in liquid nitrogen, then stored at -80 °C for
autoradiographic analysis (see details in Chapter 5).

23

2.5 Statistical analysis
A power analysis (at a power of 80%) for determining the animal numbers per group
(n=12 rats/group) was completed before the experiment, based on previous
experimental data in our laboratory. Statistical analysis was performed using SPSS
(Windows version 17.0, SPSS Inc., Chicago). The Kolmogorov-Smirnov test was
used to examine the distribution of data from all experiments. Two–way ANOVAs
(OLANZAPINE × BETAHISTINE) were used to examine behaviour, fat, receptor
binding density and hormone levels. Three-way repeated ANOVAs (OLANZAPINE
× BETAHISTINE × DAYS) were applied to examine accumulated weight gain, food
and water intake data. Multiple comparisons were performed using post-hoc
Dunnett-T tests. Pearson’s correlation test was used to assess the relationships of
non-parametric data. All data are expressed as mean ± SEM, and statistical
significance was accepted when p<0.05. Radioactive ligand binding signals were
expressed as fmoles/mg of tissue equivalent (see Chapter 5).
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CHAPTER 3
REDUCING OLANZAPINE-INDUCED SIDE EFFECTS USING
BETAHISTINE
3.1 Introduction
As reviewed in Chapter 1, in controlled studies atypical antipsychotics have
demonstrated comparable or even slightly better global clinical efficacy in the acute
treatment of schizophrenia compared to haloperidol, while they perform significantly
better than a placebo in reducing positive symptoms (Lieberman et al., 2005; Patel et
al., 2009). Olanzapine as an atypical antipsychotic drug has demonstrated an
improvement in the domains of positive and negative symptoms secondary to
psychosis and certain cognitive symptoms such as attention, executive functioning
and working memory of schizophrenia (Lieberman et al., 2005). However, it leads to
a common side effect of body weight gain/obesity, which can result in more
hazardous complications such as cardiovascular disease and metabolic disorders
(Nasrallah, 2003). However, there is currently no effective way to reduce the
antipsychotic-induced weight gain/obesity side effect. Olanzapine is a potent
histamine H1 receptor antagonist, and high H1 receptor affinity is a predictor for the
development of the antipsychotic-induced weight gain/obesity side effect. On the
other hand, the H1 receptor agonist, betahistine, acts as a modulator of the
histaminergic system and has both H1-agonistic and H3-antagonistic activity in the
brain (Yoshida et al., 2000; Fossati et al., 2001), which has been shown to be
effective in reducing body weight gain in obese rats (Machidori et al., 1992). In this
chapter, I examined the effects of adjunctive treatment of betahistine on reducing the
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olanzapine-induced body weight gain side effect. It has been suggested that enhanced
energy intake and reduced energy expenditure may contribute to a positive energy
balance in schizophrenia patients (Eder et al., 2001). Therefore, body weight, food
intake and locomotor activity of rats were measured in this experiment.

3.2 Materials and methods
3.2.1

Animals and drug treatment

The procedures of animal housing, drug treatment and histology have been described
in Chapter 2. In brief, female Sprague Dawley rats (n=12-13/group, see the reason in
Chapter 2) were administered orally with vehicle (control), olanzapine (3 mg/kg/day),
betahistine (8 mg/kg/day), or olanzapine combined with betahistine (O+B) three
times per day for two weeks.

3.2.2

Body weight, food and water intake

Body weight, food intake and water intake of the rats were measured and recorded
once every two days. Feeding efficiency of the rats (body weight gain/food
consumed) was also calculated and analysed.

3.2.3

Intra-peritoneal glucose challenge test

The intra-peritoneal glucose challenges were performed on day 7 of the treatments.
After 10-12 hours fasting, rats were given an intra-peritoneal glucose injection
(1g/kg body weight). Blood samples were collected immediately before glucose
injection (0 minute) and at 30, 60, 90 and 120-minutes post-injection for glucose
challenge test. The 30-minute time interval was selected according to a previous
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report by Albaugh and colleagues (2006), who found a significant difference in
glucose only after 30 minutes in rats under similar conditions (Albaugh et al., 2006).

Method for Blood Sampling: blood was collected from a wound at the tip of the rat
tail for glucose challenge test. Bleeding was stopped using a bandage until the next
blood sample was taken (Albaugh et al., 2006). Blood glucose was measured at
different time points using Accu-Chek blood glucose monitor (Roche Diagnostics
Group, Mannheim, Germany).

3.2.4

Open field test

The open field test was performed on day 12 of drug treatment in order to determine
whether olanzapine and/or betahistine could influence the locomotor activity of rats,
which is related to energy expenditure. A rat was placed in the centre of a black
rectangular arena (60×60cm2, 40 cm high), which was exposed to an average lighting
of 25 lux. A video camera was used to record the behaviour of the rats for 30 minutes
from the top of the arena. The locomotor activity of the rats was analysed using
EthoVision Color-Pro software (Noldus Information Technology, Wageningen, the
Netherlands) (du Bois et al., 2008) (Figure 3.1A).The arena was divided into central
and peripheral zones. moved distance (total, central and peripheral; cm), velocity
(total, central and peripheral; cm/s), latency to leave the centre of the arena, duration
(second), in-zone frequency and rearing frequency were measured in the central and
peripheral zones separately (Figure 3.1B). In nine rats (five from sole olanzapine and
four from O+B groups), behavioural data were not recorded due to video camera
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failure. Thherefore, onnly some of the data fro
om the sole olanzapine (n=7) and O+B
O cotreatment (n=8) groupps was able to be analy
ysed.
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Figure 3.11 A: Exam
mples of loccomotor acctivities froom rats in the four trreatment
groups. The
T
locomootor activitiies in the open fieldd test weree traced ussing the
Ethovisionn software. (O+B: co-treatment of
o olanzapinne and betaahistine). B:: Central
and periphheral zoness of arena were
w
defined for analyysing locom
motor activitty in the
open fieldd test.
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3.2.5

Measurements of adipose tissue, body and femur length

After the rats were sacrificed, white adipose tissue (WAT) including perirenal,
periovary and inguinal fat, as well as sub-scapular brown adipose tissue (BAT) were
dissected and individually weighed (g). Body length and femur length were also
measured and recorded to examine the effect of body growth on body weight of rats.

3.2.6

Statistical analysis

Details of statistical analyses are outlined in Chapter 2. In brief, Three way repeated
ANOVAs (OLANZAPINE × BETAHISTINE × DAYS as repeated measures) were
applied to analyse accumulated body weight gain, food and water intake data. Two–
way ANOVAs (OLANZAPINE × BETAHISTINE) was used to analyse glucose
level, behaviour and fat data. Multiple comparisons were performed using post-hoc
Dunnett-T tests. Pearson’s correlation test was used to examine the relationships
among the measurements. All data are expressed as mean ± SEM, and statistical
significance was accepted when p<0.05.

3.3 Results
3.3.1

Body weight

Figure 3.2A presents the development of body weight gain during the two weeks
treatment. A three-way repeated ANOVAs (OLANZAPINE × BETAHISTINE ×
DAYS as repeated measures) observed significant main effects of DAYS
(F7,308=145.679, p=0.000), OLANZAPINE factor (F1,44=31.887, p=0.000), and a
tendency to be significant with the BETAHISTINE factor (F1,44=3.167, p=0.082) on
accumulated body weight gain. There was significant interaction between the
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OLANZAPINE factor and DAYS (F7,308=19.489, p=0.000), between the
OLANZAPINE and BETAHISTINE factors (F1,44=3.958, p=0.053), as well as
among all three factors (F7,308=2.987, p=0.005) (Figure 3.2A).

Post-hoc tests showed that body weight gain during the two week period was
significantly greater in the sole olanzapine group (p=0.000) compared to controls
(Figure 2A). Further analyses revealed that sole olanzapine treatment significantly
increased body weight gain, occurring after four days of treatment with olanzapine
and lasting for the rest of the treatment period (all p=0.000). On the other hand, O+B
co-treatment groups had lower body weight gain than the sole olanzapine group (33%) (p=0.015). It is important that, compared to sole olanzapine group, O+B cotreatment significantly decreased body weight gain on treatment day 10 (p=0.042)
and day 14 (p=0.015), and it tended to be significant in reducing body weight gain on
day six (p=0.052), day nine (p=0.060) and day twelve (p=0.071) (Figure 3.2A).

The figure 3.2B shows the total body weight gain of the four groups of rats at the end
of the drug treatment. It showed a significant increase in total body weight following
sole olanzapine treatment (60% increase; p=0.000), and a trend to be significant in
the O+B co-treatment (p=0.055), compared to controls. It also illustrates that the rats
in the O+B co-treatment group had a significantly lower body weight gain compared
to the sole olanzapine treatment group (33% decrease; p=0.015) (Figure 3.2B) (Table
3.1). No significant difference was demonstrated between the controls and sole
betahistine-treated rats. Therefore, co-treatment of betahistine was effective to reduce
the body weight gain side effect induced by olanzapine.
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Figure 3.2 A: Cumulative Body Weight Gain (mean±SEM, g) of female Sprague
Dawley rats treated with olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), cotreatment (O+B) or control (vehicle) for 14 days. B: Total Body Weight Gain
(mean±SEM, g) after 14 days of treatment. **p<0.01 vs. control, #p<0.05 vs.
olanzapine.
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3.3.2

Food intake

When the accumulated food intake of was compared, the three-way repeated
ANOVAs (OLANZAPINE × BETAHISTINE × DAYS as repeated measures)
demonstrated significant main effects of the OLANZAPINE factor (F1,42=22.668,
p=0.000) and DAYS (F6,252=4106.666, p=0.001), as well as a significant interaction
between DAYS and the OLANZAPINE factor (F6,252=21.149, p=0.000), and
between DAYS and the BETAHISTINE

factor (F6,252=2.588, p=0.019) (Figure

3.3A).

Similar to the accumulated body weight gain, post-hoc analysis revealed that the
accumulated food intake of rats significantly increased in the sole olanzapine
treatment group (p=0.001), compared to controls (Figure 3.3A). Further analysis
indicated significantly greater accumulated food intake after four days of sole
olanzapine treatment (p<0.05).

There was a significant effect of the OLANZAPINE factor on total accumulated food
intake (F3,42=9.244, p=0.000) (Figure 3.3B). Post-hoc analysis revealed a significant
increase in accumulated food intake following sole olanzapine treatment only (+15%
increase; p=0.001) compared to control (Figure 3.3B), and the O+B co-treatment
group tended to be significant (p=0.085) (Figure 3.3B) (Table 3.1). Although the rats
with O+B co-treatment tended to have lower food intake than the sole olanzapinetreated rats during this period of drug treatment (Figure 3.3A), the differences were
not significant.
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Figure 3.3 A: Cumulative Food Intake (mean±SEM, g) of female Sprague Dawley
rats treated with olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment
(O+B) or control (vehicle) for 14 days. B: Total Food Intake (mean±SEM, g) after 14
days of treatment. **p<0.01 vs. control, *p<0.05 vs. control.
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3.3.3

Feeding efficiency

There were significant effects of the OLANZAPINE factor (F1,42=25.379, p=0.000)
and interaction between the OLANZAPINE and BETAHISTINE factors (F1,42=8.767,
p=0.005) on feeding efficiency (grams of accumulated body weight gain/grams of
accumulated food intake) (Figure 3.4). Feeding efficiency of rats was significantly
increased in the sole olanzapine treated group (p=0.000) and O+B co-treatment
group (p=0.043), but not the sole betahistine treatment group (p>0.05), compared to
the control group (Figure 3.4). It is important that, compared to the sole olanzapine
treatment group, O+B co-treatment significantly reduced feeding efficiency (31%
decrease; p=0.032). In addition, there was a significant difference in the sole
olanzapine and sole betahistine treatment groups (p=0.000) (Figure 3.4). Therefore,
co-treatment of betahistine was effective in decreasing feeding efficiency compared
to the sole olanzapine treatment.

Figure 3.4 Feeding Efficiency (weight gain/food intake±SEM, g) of female Sprague
Dawley rats treated with olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), cotreatment (O+B) or control (vehicle) for 14 days. **p<0.01 vs. control, #p<0.05 vs.
olanzapine.
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3.3.4

Water intake

A three-way repeated ANOVAs (OLANZAPINE × BETAHISTINE × DAYS as
repeated measures) of accumulated water intake only revealed a significant main
effect of DAYS (F6,264=1415.886, p=0.000), but not the OLANZAPINE factor
(F1,44=0.189, p=0.666) and BETAHISTINE factor (F1,44=0.562, p=0.457) (p>0.05).
There was also no interaction between the OLANZAPINE and BETAHISTINE
factors (F1,44=1.547, p=0.220), and among all three factors (F6,264=1415.886, p=0.099)
(Figure 3.5) (Table 3.1). In conclusion, no water intake difference was found among
the groups in the two weeks experiment.

Figure 3.5 Cumulative Water Intake (mean±SEM, ml) of female Sprague Dawley
rats treated with olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment
(O+B) or control (vehicle) for 14 days.
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Table 3.1 Mean body weight, food intake, water intake, fat pad mass (mean ± SEM)
in female Sprague Dawley rats treated with olanzapine (3 mg/kg/day) and/or
betahistine (8 mg/kg/day) or control (vehicle) for 14 days.

Control

Olanzapine Betahistine

O+B

Body Weight (g)
IBW

219.24 ± 3.43

220.80 ± 3.31

217.51±3.52

218.96 ± 3.42

FBW

231.52 ± 4.99

250.63 ± 4.29**

231.28 ± 3.52

239.13 ± 4.72

BWG

12.28 ± 2.46

29.82 ± 2.14**

13.78 ± 1.47

20.17 ± 2.99#

286.83 ± 7.29

337.17 ± 7.60*

280.15 ± 7.26

314.66±12.30

346.66± 16.63

360.59 ± 21.21

356.09 ± 20.63

321.87±14.78

Perirenal

2.26 ± 0.22

3.07 ± 0.32

2.11 ± 0.25

2.90 ± 0.30

Periovary

2.95 ± 0.33

3.66 ± 0.39

2.44 ± 0.18

3.23 ± 0.26

Inguinal

2.36 ± 0.17

3.30 ± 0.39*

2.05 ± 0.15

3.35 ± 0.29*

Total Intra-abdominal Fat

5.22 ± 0.51

6.73 ± 0.67

4.54 ± 0.40

6.14 ± 0.45

Total White Fat

7.58 ± 0.61

10.02 ± 1.01

6.60 ± 0.5

9.49 ± 0.70

Brown Fat

0.22 ± 0.03

0.24 ± 0.02

0.20 ± 0.02

0.22 ± 0.02

Total White Fat / FBW (%)

3.26 ± 0.23

3.99 ± 0.38

2.85 ± 0.21

3.96 ± 0.26

Body Length (cm)

19.29 ± 0.23

19.16 ± 0.21

19.28 ± 0.20

19.42 ± 0.21

Femur Length (cm)

4.81 ± 0.06

4.84 ± 0.05

4.86 ± 0.05

4.96 ± 0.07

AFI (g)
AWI (ml)

Fat Pad Mass (g)

*p<0.05, **p<0.01 vs. Control, #p<0.05 vs. olanzapine. IBW: initial body weight,
FBW: final body weight, BWG: body weight gain, AFI: accumulated food intake,
AWI: accumulated water intake.
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3.3.5

Fat deposits

3.3.5.1 Individual fat pad mass
The two-way ANOVAs (OLANZAPINE × BETAHISTINE) showed that there were
significant effects of the OLANZAPINE factor on the perirenal (F1,44=8.495,
p=0.006), periovary (F1,44=6.285, p=0.016) and inguinal (F1,44=17.481, p=0.000) fat,
but no difference was found in sub-scapular brown fat mass. However, there was no
significant effect of BETAHISTINE on any fat pad mass (Figure 3.6A, B, C & D)
(Table 3.1).

Post-hoc analysis revealed a significantly higher inguinal fat mass following sole
olanzapine treatment (p=0.046) and O+B co-treatment groups (p=0.031) compared to
control. However, the sole betahistine group was no different from the control group
(Figure 3.6C). A significant difference was found between the co-treatment group
and sole betahistine treatment rats (p=0.004) (Figure 3.6C). With the perirenal and
periovary fat, sole olanzapine treatment tended to increase the fat mass of rats more
than in the control group (Figure 3.6A & B). O+B co-treatment had less fat than the
sole olanzapine group, but this was not significant (Figure 3.6A & B). However,
there was no significant difference in sub-scapula brown fat mass between treatment
groups and control (Figure 3.6D) (Table 3.1).
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Figure 3.6 Fat Mass (mean±SEM, g) of female Sprague Dawley rats treated with
olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment (O+B) or control
(vehicle) for 14 days of treatment. A: Perirenal Fat, B: Periovary Fat, C: Inguinal Fat,
D: Sub-scapular Fat.* p<0.05 vs. control.
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3.3.5.2 Combined white fat mass
In terms of intra-abdominal fat (the sum of perirenal and periovary) and total white
fat mass (the sum of periovary, perirenal and inguinal fat mass), there were
significant effects of the OLANZAPINE factor on total intra-abdominal fat
(F1,44=8.944, p=0.005) and total white fat mass (F1,44=13.378, p=0.001) (Figure 3.7A
& B) (Table 3.1).

Post-hoc analyses observed that the sole olanzapine group tended to have more total
white fat mass than the control group (p=0.058). However, the O+B co-treatment
group rats had less fat than the sole olanzapine group, but this was not significant
(Figure 3.7B). In terms of intra-abdominal fat, the sole olanzapine group had a larger
amount of fat than the control group. Similarly, the co-treatment group had a smaller
amount of fat than the sole olanzapine group. However, both of them were not
significantly different (Figure 3.7A) (Table 3.1).

As a result, both the sole olanzapine and O+B co-treatment rats had more fat than the
other two groups. Although the co-treatment group had less fat than the sole
olanzapine group, no significance was found.
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Figure 3.7 Fat Mass (mean±SEM, g) of female Sprague Dawley rats treated with
olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment (O+B) or control
(vehicle) for 14 days. A: Intra-abdominal Fat Mass, B: White Fat Mass.
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3.3.5.3 Body and femur length
Figure 3.8 illustrates the body length and femur length data of all treatment groups.
There were no effects of olanzapine and/or betahistine on the body or femur length
(p=0.893 and 0.233, respectively) (Figure 3.8A & B) (Table 3.1). Therefore, there
was not any difference in the body development between the groups.
A

B

Figure 3.8 Body and Femur length (mean±SEM, cm) of female Sprague Dawley rats
treated with olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment (O+B)
or control (vehicle) for 14 days. A: Body Length, B: Femur Length.
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3.3.6

Intra-peritoneal glucose tolerance test

The three-way ANOVAs (OLANZAPINE × BETAHISTINE × TIME as repeated
measures) showed significant main effects of testing TIME (F4,144=83.505, p=0.000),
and an interaction between testing TIME and OLANZAPINE factor (F2,88=4.368,
p=0.002) on the glucose levels, but no effect of BETAHISTINE and no interaction
between BETAHISTINE and OLANZAPINE factors. As presented in the Figure 3.9,
there was no significant difference in the fasting glucose (all at ~6 fmole/ml)
between groups. The glucose levels reached the maximum at 30 minutes after
glucose injection (1g/kg body weight). The glucose levels declined to 6.5 fmole/ml at
120 minutes in all the groups.

Further analysis of the glucose area under curve (AUC) by a two-way ANOVA
(OLANZAPINE × BETAHISTINE) showed that there was a tendency towards a
significant effect of OLANZAPINE on the AUC (F1,36=3.611, p=0.065). Since there
was no significant effect of BETAHISTINE and no significant interaction between
the two factors, data from the two groups with olanzapine treatment (sole olanzapine
and O+B co-treatment) were combined to compare with the combined data of the
two non-olanzapine (control and sole betahistine) groups. It showed that olanzapine
tended to have a significantly lower AUC (848.2±16.9 fmol/ml) than non-olanzapine
groups (899.2±20.1 fmole/ml; t=1.942, df=38, p=0.060) (Figure 3.9).
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Figure 3.9 Blood glucose levels (fmole/ml±SEM) of female Sprague Dawley rats
treated with olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment (O+B)
or control (vehicle) for 14 days.
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3.3.7

Open field test

3.3.7.1 Distance moved and velocity
Two-way ANOVAs (OLANZAPINE × BETAHISTINE) exhibited significant
effects of the OLANZAPINE factor on distance moved (total: F1,34=23.284, p=0.000;
central: F1,34=10.037, p=0.003; peripheral: F1,34=24.383, p=0.000), but no effect of
the BETAHISTINE factor. Also, there was a significant interaction between the two
factors on distance moved in the peripheral zone (F1,34=4.582, p=0.040), and a trend
for significance on total distance moved (F1,34=3.636, p=0.065) (Figure 3.10A)
(Table 3.2). In terms of the velocity, a significant decrease was found in the
OLANZAPINE factor (total: F1,34=26.032, p=0.000; central: F1,34=4.462, p=0.042;
peripheral: F1,34=31.010, p=0.000) (Figure 3.10B). In addition, the interactions of the
two factors were being significant for total and peripheral velocity (total: F1,34=3.190,
p=0.083; peripheral: F1,34=3.239, p=0.081) (Figure 3.10B) (Table 3.2).

The results showed that the distance moved significantly decreased in the cotreatment group compared to the control (total: -33%, p=0.003; central: -55%,
p=0.039; peripheral: -28%, p=0.003). Although the distance moved was decreased in
the olanzapine group (total: -19%, central: -39%, peripheral: -16%) compared to the
control, there was no significance (Figure 3.10A). Post-hoc analysis displayed
significant changes in rats with O+B co-treatment compared to the control group for
peripheral velocity (total: -33%, p=0.002; peripheral: -33%, p=0.001), but there was
no significant difference in velocity in the central zone 13% (p=0.550) (Figure
3.10B). In terms of the olanzapine group compared to the control group, peripheral
velocity was significantly decreased (p=0.038), and total velocity tended to be
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significant (p=0.076) (Figure 3.10B). Therefore, both the olanzapine and O+B cotreatment groups displayed less movement and velocity compared to the control, but
no significant difference was found between the olanzapine and control groups.

A

B

Figure 3.10 Data of open field test of female Sprague Dawley rats treated with
olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment (O+B) or control
(vehicle) for 14 days. A: Distance Moved (Total, Central, Peripheral, cm), B:
Velocity (Total, Central, Peripheral, cm/s). *p<0.05 vs. control, **p<0.01 vs. control.
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3.3.7.2 In-zone frequency and rearing frequency
OLANZAPINE differed in its effects on the central and peripheral in-zone frequency
(central: F1,34=14.081, p=0.001; peripheral: F1,34=14.056, p=0.001) (Figure 3.11A),
and rearing frequency (central: F1,34=17.382, p=0.000; peripheral: F1,34=17.888,
p=0.000) (Figure 3.11B), but there was no effect of BETAHISTINE. Furthermore,
no significant interaction was found between the two factors (Figure 3.11) (Table
3.1).

Post-hoc analysis revealed a significant decrease in the rats with O+B co-treatment
compared to the control group in in-zone frequency (central: -54%, p=0.016;
peripheral: -53%, p=0.016) and rearing frequency (central: -62%, p=0.006;
peripheral: -51%, p=0.019) (Figure 3.11A & B), and there was no significant
difference found between the sole olanzapine and control groups, although sole
olanzapine appeared to be lower in Figure 3.11. There was no difference between
sole betahistine treatment and control (Figure 3.11). Therefore, both olanzapine and
O+B co-treatment groups displayed less in-zone and rearing frequency compared to
control, but no significance was found between the olanzapine and control groups.
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Figure 3.11 Data of open field test of female Sprague Dawley rats treated with
olanzapine (3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment (O+B) or control
(vehicle) for 14 days. A: In-zone Frequency (Central, Peripheral), B: Rearing
Frequency (Central, Peripheral). *p<0.05 vs. control, **p<0.01 vs. control.
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Table 3.2 Open field test in female Sprague Dawley rats treated with olanzapine (3
mg/kg/day) and/or betahistine (8 mg/kg/day) or control (vehicle) for 14 days.

Control

Olanzapine

Betahistine

O+B

Total Distance Moved (cm)

10264.1±645.7

8330.6±721.7

11360.3±573.9

6900.4±651.8**

Central Distance Moved (cm)

1801.7±329.5

1192.7±255.0

1933.4±215.1

825.0±180.4*

Peripheral Distance Moved (cm)

8462.4±367.1

7137.8±536.7

9426.9±413.6

6075.4±589.6**

Total Velocity (cm/s)

5.7±0.4

4.5±0.4

6.3±0.3

3.8±0.4**

Central Velocity (cm/s)

10.3±0.9

12.6±0.8

10.3±0.6

11.7±1.1*

Peripheral Velocity (cm/s)

5.3±0.3

4.1±0.3*

5.9±0.3

3.6±0.4**

Latency of first occurrence

26.3±5.9

18.9±6.3

22.4±6.6

14.7±3.8

Central Duration (s)

189.0±36.0

99.1±22.7

191.2±19.7

79.3±23.1*

Peripheral Duration (s)

1611.0±36.0

1701.0±22.7

1608.8±19.7

1720.7±23.1*

Central In-zone Frequency

76.6±12.6

54.1±10.6

88.1±6.8

35.1±7.2*

Peripheral In-zone Frequency

77.5±12.5

55.1±10.6

89.0±6.9

36.0±7.2*

Central Rearing Frequency

72.2±12.0

45.9±8.1

81.3±7.8

27.4±5.9**

Peripheral Rearing Frequency

105.3±13.4

70.3±10.7

130.0±14.2

51.3±8.9*

Data are expressed as mean ± SEM. *p<0.05 compared to control.
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3.3.8

Correlations

3.3.8.1 Relationships among body weight, food intake and fat
There was a highly significant correlation between total body weight gain and total
food intake (r=0.702, p=0.000, Figure 3.12A) and feeding efficiency (r=0.948,
p=0.000, Figure 3.12B). Furthermore, intra-abdominal and total fat mass were also
significantly correlated with total body weight gain (r=0.319, p=0.027; r=0.329,
p=0.022, Figure 3.12C & D).

Total Food Intake (g)

A
450
400
350
300
250

r=0.702, p<0.01

200
0

10

20

30

40

50

Total Body Weight Gain (g)

Feeding Efficiency

B
0.16
0.14
0.12
0.1
0.08
0.06
0.04
0.02
0

r=0.948, p<0.01
0

10

20

30

40

50

Total Body Weight Gain (g)
49

C
Intra-abdominal Fat Mass
(g)

116
1
14
1
12
1
10
8
6
4
2
0

r
r=0.319,
p<
<0.05
0

10

2
20

30

40

50

Total Bod
dy Weight Gain
G
(g)

White Fat Mass (g)

D
25
20
15
10
5

r=0.329, p<
<0.05

0
0

100

20

30

40

50

T
Total
Body
y Weight Gain (g)

Figure 3..12 The corrrelations between
b
To
otal Body Weight
W
Gainn (g) and A:
A Total
Food Intakke (g), B: Feeding
F
Effficiency, C:: Intra-abdoominal Fat M
Mass (g), D:
D White
Fat Mass (g).
(

50

3.3.8.2 Correlations among behaviours data and body weight, food intake and
fat
In terms of open field testing, total distance moved was negatively correlated with
total body weight gain (r=-0.360, p=0.027) (Figure 3.13A), and total white fat mass
(r=-0.346, p=0.024, Figure 3.13B). Furthermore, velocity was negatively correlated
with total body weight gain (r=-0.383, p=0.018) (Figure 3.13C).
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Figure 3.13 The correlations between Total Distance Moved (cm) and A: Total Body
Weight Gain (g), B: White Fat Mass (g), C: Correlation between Total Body Weight
Gain (g) and Total Velocity (cm/s).
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3.4 Discussion
In summary, the results from this chapter have shown that rats treated solely with
olanzapine gained three times more body weight than controls. On the other hand,
sole betahistine treatment had no effect. Olanzapine-treated rats had higher food
intake than controls. The co-treatment of olanzapine and betahistine had lower
feeding efficiency than sole olanzapine treatment. The co-treatment of olanzapine
and betahistine reduced the body weight gain induced by olanzapine treatment by
50%. Therefore, co-treatment of olanzapine with betahistine can partially reduce the
weight gain side effect induced by olanzapine. Rats in both the sole olanzapine and
co-treatment groups were less active than rats treated with betahistine and control,
which suggests that the lower activity levels contributed partially to the weight-gain
induced by olanzapine, however betahistine treatment did not affect locomotor
activity.

3.4.1

Body weight gain

Our results show that the body weight of the rats was substantially greater in the sole
olanzapine group compared to controls since 4 days after treatment. This result is
consistent with previous studies on the olanzapine induced body weight gain side
effect in rats and humans (Allison et al., 1999; Goudie et al., 2002; Fell et al., 2004;
Cooper et al., 2005; Kalinichev et al., 2005; Albaugh et al., 2006; Huang et al., 2006;
Choi et al., 2007; Han et al., 2008; Nasrallah, 2008). A recent study from Han and
colleagues showed that one week of olanzapine treatment (1.5mg/kg/day) in female
rats led to a threefold increase in body weight, and this significance was maintained
up to eight weeks of treatment (Han et al., 2008). In addition, the body weight gain
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results in the present study also in agreement with a recent report from our laboratory
(Weston-Green et al., 2010), showing that after four days of olanzapine treatment,
there is a significant increase in body weight in rats treated with various dosages (1.5,
3, 6mg/kg/day), but not at a low dosage of 0.75 mg/kg/day. In the present study, it
was clearly shown that the sole olanzapine group gained three times more body
weight compared to the control after two weeks of treatment.

Betahistine has been used to reduce weight gain in obese rats (Szelag et al., 2001).
However, in the present study, sole betahistine administration to female rats did not
have any effect on body weight during the two weeks of experiments. This is
consistent with a study on humans showing that sole betahistine treatment did not
increase patients’ body weight while olanzapine did (Poyurovsky et al., 2005). The
reasons for this discrepancy are unknown.

This is the first study in rats to show that betahistine plus olanzapine treatment can
significantly decrease olanzapine-induced body weight gain from the sixth day of the
treatment. Very interestingly, the co-treatment group didn’t completely prevent the
body weight gain induced by olanzapine treatment. Compared to the sole olanzapine
group, O+B co-treatment significantly decreased body weight, but there was still
more weight gain than the control and sole betahistine groups. The results revealed
that the combined betahistine and olanzapine treatment can only partially reduce the
body weight gain side effect induced by olanzapine. Furthermore, other parameters
such as food intake could be used to further explain the above body weight findings.
A clinical trial performed by Poyurovsky showed that schizophrenia patients co54

administrated with olanzapine (10mg/day) and betahistine (48mg t.i.d.) for six weeks
gained less weight than those only treated with olanzapine in schizophrenia patients
(Poyurovsky et al., 2005).

There was no difference in body and femur length between the groups in this
experiment, demonstrating that none of the drug treatments, including olanzapine
and/or betahistine or control, had an influence on animal growth.

3.4.2

Food intake and feeding efficiency

Olanzapine treatment increased total food intake after two weeks’ administration in
rats. Similar results were observed in human schizophrenia patients (Eder et al., 2001;
Meltzer et al., 2003). In rats, olanzapine treatment has been found previously to
induce a significant increase in food intake in female rats (Thornton-Jones et al.,
2002; Arjona et al., 2004; Albaugh et al., 2006; Huang et al., 2006; Choi et al., 2007;
Davoodi et al., 2009; Deng et al., 2010). In this study, a significantly positive
correlation of body weight gain and food intake has been found. In terms of feeding
efficiency (amount of weight gain divided by the amount of food intake), there was a
significant increase in the sole olanzapine group compared with controls. Therefore,
data form this study experiment and previous studies all suggest that increased food
intake contributed largely to the olanzapine-induced body weight gain.

No significant difference in food intake and feeding efficiency has been observed in
the sole betahistine group compared to the control in this study. It is interesting that,
similar to the body weight gain data, the amount of food intake in the co-treatment
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group was always lower than the sole olanzapine-treated group during the
experimental period, but higher than the control and sole betahistine groups. Also of
interest is the fact that the feeding efficiency of the co-treatment group was higher
than the control group, but significantly lower than the olanzapine group. These
results suggest that the ability of betahistine to decrease olanzapine-induced body
weight gain is at least partially attributed to reduced food intake and reduced feeding
efficiency.

3.4.3

Water intake

Polydipsia (excessive thirst) is a serious complication for schizophrenia patients.
Compared with typical antipsychotics, atypical antipsychotics could more or less
relieve this syndrome in schizophrenia (Littrell et al., 1997; Kruse et al., 2001;
Bersani et al., 2007). However, there was no significant difference in water intake
between the groups in the present experiment. This result is consistent with previous
studies by our laboratory (Han et al., 2008; Weston-Green et al., 2010) and other
laboratories (Fell et al., 2004; Stefanidis et al., 2008).

3.4.4

Intra-peritoneal glucose tolerance test

As discussed in Literature Review, antipsychotic treatments may cause a series of
metabolic side effects, such as type 2 diabetes (Newcomer, 2004; Lieberman et al.,
2005). The results showed that olanzapine and betahistine treatment did not affect
overnight (10-12 hours) fasting glucose levels after seven days treatments.
Previously, it has been reported that two weeks treatment of olanzapine reduced the
glucose level (Weston-Green et al., 2010). It is possible that a longer treatment
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(>seven days) is needed to have an effect on fasting glucose levels. However, one
acute study also showed that one day treatment of olanzapine reduced glucose levels
after five hours’ fasting (Albaugh et al., 2006). Therefore the fasting period is also
important in detecting changes in fasting glucose. In glucose tolerance tests,
olanzapine-treated rats tend to have a lower blood glucose level at 30 and 60 minutes
after glucose change, but returned to a normal level at 90 minutes. Taken together,
olanzapine treated rats tend to have a lower AUC (Area Under Curve). This result
was similar with Albaugh and colleagues’ study which found the glucose levels of
olanzapine treated (both acute and two weeks) rats were lower than control animals
at all time points (Albaugh et al., 2006). They also found that rats with two weeks’
treatment of olanzapine showed decreased insulin sensitivity, but rats with acute
treatment had no changes in insulin sensitivity (Albaugh et al., 2006). Further study
is required to examine the time course of insulin sensitivity changes after olanzapine
treatment.

3.4.5

Fat pad mass, body and femur length

In order to detect the effects of drug treatment, adiposity, white adipose tissue,
including inguinal, perirenal and periovary as well as sub-scapular brown adipose
tissue, were collected and individually weighed from rats. The sole olanzapine group
was found to have more fat mass than the control and sole betahistine groups. In
addition, in the sole olanzapine group, the fat mass increase was observed only in the
intra-abdominal white fat (periovary plus perirenal fat) and subcutaneous white fat.
These results were consistent with previous studies (Fell et al., 2004; Cooper et al.,
2005). Furthermore, an increase in white adiposity was also seen in rodents treated
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with other atypical antipsychotic drugs such as clozapine (Fell et al., 2007; Cooper et
al., 2008). In the present study, there was a significant positive correlation between
total body weight gain and total white fat mass. This suggests that the increased rat
fat pad mass was highly associated with the olanzapine-induced body weight gain
side effect.

In the present study, sole betahistine treatment had no effect on white fat mass. The
co-treatment group had slightly decreased total white fat, but this was not statistically
significant, which suggests that betahistine possibly does not have much effect on
white fat mass.

Furthermore, olanzapine was found to have no effect on sub-scapular fat mass
(brown adipose tissue, BAT). This result is consistent with a previous study in our
laboratory (Weston-Green et al., 2010). In contrast to white adipose tissue (WAT),
BAT is primarily used for thermo-regulation. Stefanidis and colleagues found that
olanzapine-treated female rats continued to increase food intake and body weight,
which has a partial relationship with the function of BAT (Stefanidis et al., 2008).
Using biotelemetry devices, Stefanidis et al. measured the temperature of BAT, and
found that BAT temperature was decreased after the onset of olanzapine treatment in
female rats. Following chronic olanzapine treatment, the temperature continually
decreased due to reduced physical activity, and therefore UCP1 (Uncoupling protein
1) expression in inter-scapular BAT also declined. The authors argued that decreased
BAT temperature may have partially contributed to olanzapine induced body weight
gain in rats (Stefanidis et al., 2008). In the present study, only the fat mass, but not
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the function/temperature, was measured. It would be interesting to measure the
temperature of BAT in further studies. Nevertheless, this is the first study to examine
the effect of betahistine on the BAT mass, and the results showed that betahistine did
not affect BAT mass.

3.4.6

Open field test

By tracing the locomotor activity of rats in the open field test arena, this study
showed that olanzapine but not betahistine reduced animal activities. Compared to
the control group, olanzapine treatment exhibited a trend of diminished locomotor
activity in rats. Olanzapine reduced both distance moved and velocity. Previous
studies revealed a similar result of decreased locomotor activity in animals treated
with olanzapine (Arjona et al., 2004; Chintoh et al., 2008b). Recently, colleagues
from our laboratory tested the dose dependent effect of olanzapine (using a dosage
range of 0.75-6 mg/kg/day) on locomotor activity, and found that the higher the
dosage was the stronger the effects on locomotor activity of rats. They found that 3
mg/kg/day significantly decreased activity of the rats (Weston-Green et al., 2010). In
the present study, there was only a trend, but no significant decrease in activity in the
sole olanzapine group, which was possibly due to a technical reason failure that
made some data in the olanzapine treatment group lost. During the open field test,
the animal behaviours of nine rats (five from the sole olanzapine group and four from
the O+B co-treatment group) were not recorded due to camera failure. Therefore, we
only had behavioural data from seven rats in the sole olanzapine group. The sample
size may not enough to detect the significance in the sole olanzapine group. The O+B
co-treatment group showed significantly decreased activity of rats compared to the
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controls, but not the sole olanzapine group. The ANOVA detected an effect of
olanzapine treatment, but not betahistine, and no interaction between the two factors.
This suggests that the decreased activity in the co-treatment group is due to
olanzapine treatment.

It is interesting that there was a negative correlation among locomotor activity, body
weight and white fat mass, which suggests that the weight gain/obesity induced by
olanzapine treatment is at least partially attributable to a decrease in energy
expenditure. In fact, in the clinic, schizophrenia patients treated with olanzapine
would lead to less vigorous physical exercise (Suzanne et al., 2007; Treuer et al.,
2009) and affect energy expenditure (Allison et al., 1999), which contributed to a
high risk of body weight gain/obesity and its sequelae such as metabolic side effects
(Green et al., 2000).

In the present study, betahistine had no effect on any of the parameters measured in
the open field testing, which suggests that betahistine had no effect on the locomotor
activity of rats. However, a previous study revealed that betahistine treatment
increased the locomotor activity of rats at a high dose (10 or 25 mg/kg) (Alvarez et
al., 1993). Further experiments are needed to reveal what dosage of betahistine is
necessary for influencing locomotor activity.

Co-treatment of olanzapine with betahistine significantly decreased the activity of
rats (33%) in this study, but co-treatment with betahistine was no different from sole
olanzapine treatment. This suggests that reduced locomotor activity by olanzapine
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treatment cannot be improved by betahistine. In fact, the co-treatment group had
slightly less activity. These results may explain why betahistine can only partially
improve olanzapine-induced body weight gain, because it does not affect on
locomotor activity, and active energy expenditure.

3.5 Summary
In summary, this chapter has shown that olanzapine-treated rats have much higher
body weight gain, food intake, and white fat mass, but less locomotor activity than
controls. However, sole betahistine treatment has no influence on these parameters.
Co-treatment with olanzapine and betahistine partially improved body weight gain
side effects. Compared to the sole olanzapine treatment, co-treatment of olanzapine
with betahistine (at a dose of 8 mg/kg/day) partially reduced feeding efficiency, but
had no effect on locomotor activity, which may explain its partial effect in reducing
olanzapine-induced weight gain. Further studies may be conducted to examine
whether a long-term experiment (for example five weeks) or a higher dose of
betahistine could have a stronger effect on reducing the olanzapine-induced weight
gain side effect.
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CHAPTER 4
EFFECTS OF OLANZAPINE AND BETAHISTINE
TREATMENTS ON PLASMA INSULIN AND PYY IN THE RAT
4.1 Introduction
As reviewed in Chapter 1, appetite hormones such as peptide YY (PYY) and insulin
are involved in the regulation of food intake and obesity (Meyer, 2002). Previous
studies have shown that antipsychotic drugs (including olanzapine) could influence
these hormone levels in schizophrenia patients and in animal models (Lieberman et
al., 2005; Jin et al., 2008). For example, although there is evidence that olanzapine
induces alterations in PYY binding in regions of the brain such as the medial
amygdaloid nucleus and medial geniculate nucleus (Wang and Huang, 2008), the
effect of olanzapine on plasma PYY level remains unknown. The reports on the
effect of olanzapine on plasma insulin appear inconsistent: chronic olanzapine
treatment increased insulin levels, reduced insulin sensitivity and led to insulin
resistance (Perez-Iglesias et al., 2008; Wu et al., 2008), however acute treatment of
olanzapine decreased plasma insulin levels in rats (Chintoh et al., 2008b). To date,
there are no studies investigating the effects of betahistine on hormone levels, and
the effect of co-treatment of betahistine with olanzapine on hormonal levels remains
unknown. Therefore, the aim of this chapter is to examine the effects of olanzapine
and/or betahistine on circulating insulin and PYY.
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4.2 Materials and methods
4.2.1

Animals and drug treatment

Details relating to animal housing, drug administration and experimental design have
been described in Chapter 2. Briefly, forty-nine female Sprague Dawley rats (n=1213/group, see the details in Chapter 2) were administered with olanzapine (3
mg/kg/day), betahistine (8 mg/kg/day), co-treatment olanzapine with betahistine (at
same dosages as first 2 groups) or vehicle (control), orally 3 times per day for two
weeks.

4.2.2

Blood sampling

Rats were sacrificed on day 15 of treatments using CO2 asphyxiation after 10-12
hours fasting. Blood samples were immediately collected from the left ventricle of
the heart. Blood samples were collected in tubes containing EDTA (an anticoagulant),
and centrifuged at 3000 × g for 5 min at 4 ºC. Plasma was aliquoted, and stored in 20 ºC freezer for plasma hormonal measurements.

4.2.3 Plasma hormonal measurements
Fasting plasma insulin and PYY levels were measured by immunoassay using the
Rat Gut Hormone Panel kit (Milliplex™ Map) from Luminex® (Millipore, Billerica,
MA, USA). 50 µl of plasma samples were analyzed using antibody-immobilized
beads specific for the hormones insulin and PYY. The hormonal quantification was
performed using the Luminex100 (Luminex, Austin, TX). The results were based on
fluorescent reporter signals. The median fluorescent intensity (MFI) data was
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obtained from Luminex® and analyzed using a weighted 5 parameter logistic or spine
curve-fitting method for calculating analyte concentrations in samples.

4.2.4

Statistical analysis

The details of statistical analyses are outlined in Chapter 2. In brief, two–way
ANOVAs (OLANZAPINE × BETAHISTINE) were used to analyse the hormonal
data. Multiple comparisons were examined using independent T tests. Data and
figures are presented as mean ± SEM. The p<0.05 was accepted as significant value.

4.3 Results
For the fasting plasma insulin level, the two-way ANOVAs (OLANZAPINE ×
BETAHISTINE) displayed that there was a significant interaction between the
OLANZAPINE and BETAHISTINE factors (F=5.725, p=0.022), but no significant
effects of OLANZAPINE and BETAHISTINE factors themselves (both p>0.05)
(Figure 4.1A). Sole olanzapine tended to decrease the plasma insulin level
(olanzapine: 214.40±32.70 pg/ml vs. control: 318.62±42.12 pg/ml; t=1.929, df=18,
p=0.070), however sole betahistine and O+B co-treatment groups showed no
significant difference from the control group. Instead, the O+B co-treatment group
had significantly higher insulin levels than the sole olanzapine group (O+B:
375.56±67.94 pg/ml vs. olanzapine: 214.40±32.70 pg/ml; t=-2.161, df=19, p=0.044)
(Figure 4.1A).

There were no significant effects of OLANZAPINE (F1,38=3.055, p=0.226), and no
significant interaction between the OLANZAPINE and BETAHISTINE factors
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(F1,38=0.078, p=0.781). Although there was a tendency for an effect of the
BETAHISTINE factor (F1,38=3.055, p=0.089), multiple comparisons showed that
there was no significant difference between any of these treatments and control
groups (Figure 4.1B).

A

B

Figure 4.1 The fasting plasma hormone levels (pg/ml±SEM): A: Plasma Insulin, B:
Plasma PYY in female Sprague Dawley rats treated with olanzapine (3 mg/kg/day),
betahistine (8 mg/kg/day), O+B co-treatment and control (vehicle) for 14 days.
#p<0.05 vs. olanzapine.
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4.4 Discussion
As reviewed in Chapter 1, appetite hormones such as peptide YY (PYY) and insulin
are associated with obesity, and other metabolic disorders, which could be induced
by antipsychotic treatments (Meyer, 2002; Jin et al., 2008). It is suggested that
olanzapine could influence these hormonal levels in schizophrenia patients and
animals (Lieberman et al., 2005; Jin et al., 2008). However, the effects of betahistine
and co-treatment of olanzapine with betahistine on hormonal levels remain unknown.

As the glucose regulation hormone, the level of insulin could be increased after
eating. Fasting plasma insulin levels have been shown to be increased in human
obesity (Batterham et al., 2003). In the present study, it was revealed that two weeks’
treatment of olanzapine decreased fasting plasma insulin levels compared to the
control. This result was similar to another study by colleagues in our laboratory, that
found

two weeks’ treatment of olanzapine at a dosage ranging from 0.75-6

mg/kg/day decreased fasting insulin levels (Weston-Green et al., 2010). Furthermore,
recent human studies also reported that insulin secretion of schizophrenic patients
significantly decreased after olanzapine treatment for two weeks (Chiu et al., 2006;
Chiu et al., 2010). However, chronic olanzapine treatment increased insulin levels,
reduced insulin sensitivity and led to insulin resistance (Perez-Iglesias et al., 2008;
Wu et al., 2008). It has been suggested that the effects of olanzapine on insulin
secretion is time-dependent (Chiu et al. 2010). Further study is needed to reveal the
mechanisms underlying the time-course of insulin changes induced by olanzapine. It
is interesting that the O+B co-treatment had a normal insulin level which suggested
that betahistine might possibly improve insulin changes caused by olanzapine
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treatment. This finding may be explained by the binding profiles of these drugs, as
olanzapine and betahistine are a histamine H1 receptor antagonist and agonist,
respectively (Allison et al., 1999; Yoshida et al., 2000), however further studies are
necessary.

PYY appears to fulfil the function of inhibiting gastric motility, reducing appetite
and suppressing pancreatic secretion (Batterham and Bloom, 2003). The plasma
levels of PYY could be increased after food intake or decreased after fasting (Jin et
al., 2008). The body weight gain of rodents could be reduced by long-term
administration of PYY (Batterham et al., 2003). The PYY is secreted less in obese
humans than normal weight humans (Batterham et al., 2003). PYY acts through
binding to NPY receptors in the central nervous system to regulate food intake
(Schwartz and Moran, 2002; Brain and Cox, 2006). Wang and Huang (2008)
reported that PYY receptor binding density in various regions of the rat brain was
changed after 36 days’ olanzapine treatments. However, the effect of olanzapine on
plasma PYY remains unknown. The present study didn’t show any difference in drug
treatments on the level of circulating PYY, which is consistent with a recent report
(Weston-Green et al., 2010). A recent clinical study also showed that a one week
treatment of olanzapine did not affect the PYY levels in schizophrenia patients
(Vidarsdottir et al., 2010). These results suggested that short-term treatment does not
influence blood PYY levels, however further studies should investigate whether
chronic treatment of olanzapine affects blood PYY levels.
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4.5 Summary
In conclusion, this chapter has shown that olanzapine (3 mg/kg/day) tended to
decrease fasting plasma insulin level in rats, and that co-treatment with betahistine
can improve the insulin level reduced by olanzapine. Olanzapine and/or betahistine
treatment had no effect in fasting plasma PYY levels. Further studies are required to
investigate the time course of changes in insulin levels induced by olanzapine, as
well as the effects of chronic treatment of olanzapine on PYY levels.
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CHAPTER 5
EFFECTS OF OLANZAPINE AND BETAHISTINE TREATMENT
ON HISTAMINE H1 RECEPTOR BINDING IN THE RAT BRAIN
5.1 Introduction
As discussed in Chapter 1, histamine H1 receptors are extensively expressed in the
brain including the hypothalamus, which plays a significant role in energy
homeostasis. Several meta-analyses have revealed that an antipsychotic’s affinity to
the histamine H1 receptor positively correlated with its ability to cause body weight
gain (Kroeze et al., 2003; Matsui-Sakata et al., 2005). Olanzapine is a potent H1
receptor antagonist, and its high affinity for the H1 receptor is thought to contribute
to its body weight gain side effect (Allison et al., 1999; Han et al., 2008).

It is now clear that the regulation of body weight relates to both hormonal and neural
mechanisms, controlling both energy intake and expenditure (see more details in
Chapters 1 and 4). The neural mechanisms for the regulation of body weight and
energy homeostasis involve the hypothalamus, brainstem and higher brain centres
(Schwartz et al., 2000). Hypothalamic nuclei such as the arcuate hypothalamic
nucleus (Arc) and the ventromedial hypothalamic nucleus (VMH) play key roles in
the regulation of appetite, energy expenditure and body weight (Schwartz et al., 2000;
Wynne et al., 2005). Alterations in hypothalamic function can result in metabolic
disturbances such as obesity and anorexia (Almeras et al., 2004). For example,
olanzapine has been reported to reduce H1 receptor mRNA expression in the Arc and
VMH which correlated with its weight gain side effect (Han et al., 2008). In addition,
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the dorsal vagal complex (DVC) of the brainstem plays a role in controlling food
intake (Schwartz et al., 2000).

Previous studies have reported that olanzapine

treatment can modulate the neural transmission of muscarinic M2 and cannabinoid
CB1 receptors in the DVC (Deng et al., 2007; Weston-Green et al., 2008), however it
is not clear whether H1 receptors in the DVC are affected by olanzapine.

The present study has shown that co-treatment with betahistine can partially reduce
olanzapine-induced weight gain (see Chapter 3). As a histamine H1 agonist,
betahistine may compete against olanzapine through H1 receptors in the
hypothalamus and DVC to diminish its weight gain side effect. Therefore, in this
chapter, the effects of olanzapine and/or betahistine treatment on H1 receptor binding
in the hypothalamus and DVC, as well as their relationship with weight gain, were
investigated.

5.2 Materials and methods
5.2.1

Animals and drug treatment

The details of animal housing, drug administration and experimental design have
been presented in Chapter 2. In brief, forty-nine female Sprague Dawley rats (n=1213/group, see details in Chapter 2) were administered with olanzapine, (3 mg/kg/day),
betahistine (8 mg/kg/day), co-treatment olanzapine with betahistine (at same dosages
as first two groups) or vehicle (control), orally three times per day for two weeks.
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5.2.2

Histology

Brain tissue (collected from the experiment in Chapter 3) was cut at -18 °C into 14
μm coronal sections using a cryostat (Leica CM1850, Leica Microsystems,
Germany). The hypothalamus and DVC of the brainstem were obtained based on a
standard rat brain atlas (Paxinos and Watson, 1998) (Figure 5.1). These brain regions
were selected based on their involvement in the regulation of food intake and body
weight. Brain sections were thaw-mounted onto Polysine™ Microscope Slides
(Menzel GmbH & Co. KG, Braunschweig, Germany) and stored at -20 °C (Figure
5.1).

Figure 5.1 The location of brain areas sectioned in this study (Adapted from Paxinos
and Watson, 1998).
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5.2.3

Brain H1 receptor autoradiography

The following [³H]pyrilamine autoradiography procedure has been successfully
performed in our laboratory and others (Ryu et al., 1995; Han et al., 2008; Hu et al.,
In press). Brain sections containing the hypothalamus and brainstem were thawed at
room temperature, then incubated with 10nM [³H]pyrilamine (Specific activity: 25.8
Ci/mMol; PerkinElmer, Boston, MA) in 50 mM sodium potassium phosphate buffer
(pH 7.4) for 1-hour at room temperature. Non-specific binding was determined by
incubating sequential sections with 10nM [³H]pyrilamine incubation buffer, with the
addition of 2 μM triprolidine (Sigma Pharmaceuticals, Australia). Slides were
washed four times for 2 minutes in ice-cold buffer, dipped in ice-cold distilled water,
and then dried under a stream of cool air.

5.2.4

Quantification

Sections were placed in the detection chamber of a Beta-imager™ camera (Version 4,
BioSpace, Paris, France) and scanned for 3.5 hours at a high-resolution setting. One
slide with a known amount of radioactivity was used as a standard. The level of
radioactivity in the brain sections was determined by directly counting the number of
β-particles emitted from the tissue, which was performed by analysis of activity in
the brain regions of interest using a Beta Vision Plus program (BioSpace). The
radioligand binding signal was converted from counts per minute per square
millimetre (cpm/mm²) to nanocuries per milligram (nCi/mg) of tissue equivalents
(nCi/mg TE) using the previously mentioned standards (Deng et al., 2007). Specific
binding was calculated by subtracting non-specific binding from total binding. A set
of sections from each animal was stained with 0.5% cresyl violet solution (Nissl
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staining) and used for confirmation of anatomical structures. Specific brain regions
including the Arc, VMH and DVC were identified by reference to the Nissl-stained
sections and a standard rat brain atlas (Paxinos and Watson, 1998). Examples of
receptor binding images captured by the Beta-imager™ camera in this study are
presented in Figure 5.2.

Figure 5.2 Examples of histamine H1 receptor binding using a tritium labelled ligand
[³H]pyrilamine in the VMH (Ventromedial hypothalamic nucleus) and Arc (Arcuate
hypothalamic nucleus) of the hypothalamus and the DVC (Dorsal vagal complex) of
the brain stem in the rat brain.

5.2.5

Statistical analysis

The data were analysed using the SPSS program (Version 17.0, SPSS Inc., Chicago).
Two-way ANOVAs (OLANZAPINE × BETAHISTINE) were used to analyse
histamine H1 receptor binding density in relevant brain regions, including the Arc,
VMH and DVC of the rat. The post-hoc Dunnett-T test followed when data was
identified as significant. Data are expressed as mean ± SEM. Significance was
accepted when p<0.05.
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5.3 Results
VMH Two-way ANOVAs (OLANZAPINE × BETAHISTINE) showed that there
was a tendency for BETAHISTINE (F1,19=3.130, p=0.093) to have a significant
effect on H1 receptor binding density in the VMH. Betahistine tended to increase H1
binding density in this nucleus (Figure 5.3A). However, there was no significant
effect of OLANZAPINE (F1,19=0.724, p=0.405) on H1 receptor binding density in
the VMH, and no significant interaction between the two factors (F1,19=0.012,
p=0.914). Since there was no significant effect of OLANZAPINE and no significant
interaction between the two factors, data from the two groups with betahistine
treatment (sole betahistine and O+B co-treatment) were combined to compare with
the combined data of the two non-betahistine (control and sole olanzapine) groups.
It showed that betahistine tended to have a significantly increase of H1 binding
density in VMH than non-betahistine groups (betahistine: 3.22±0.16 nCi/mg vs. nonbetahistine: 2.84±0.12 nCi/mg; t=-1.874, df=21, p=0.075).

ARC No significant effect of any factor in the Arc was found in this experiment
(Figure 5.3B).

DVC In the DVC, there was a significant main effect of BETAHISTINE on H1
receptor binding density (F1,17=4.757, p=0.044) and a significant interaction between
BETAHISTINE and OLANZAPINE (F1,17=7.382, p=0.015), however there was no
significant effect of OLANZAPINE (F1,17=0.635, p=0.437) on H1 receptor binding in
this region (Figure 5.3C). Post-hoc analysis showed that sole betahistine significantly
decreased H1 receptor binding density in the DVC compared to the controls (p=0.005)
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(Figure 5.3C). However, sole olanzapine and the O+B co-treatment showed no
significant difference from the control group (both p>0.05) (Figure 5.3C).

A

VMH

B

Arc
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C

DVC

Figure 5.3 The levels of H1 receptor binding density (nCi/mg tissue; mean±SEM) in
the A: Ventromedial Hypothalamic Nucleus (VMH), B: Arcuate Hypothalamic
Nucleus (Arc), and C: Dorsal Vagal Complex (DVC) of rats treated with olanzapine
(3 mg/kg/day), betahistine (8 mg/kg/day), co-treatment (O+B) or control (vehicle)
for 14 days. * p<0.05 vs.control.
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5.4 Discussion
The present study showed that sole betahistine treatment significantly decreases H1
receptor binding density in the DVC, with a tendency to increase histamine H1
receptor binding density in the VMH, but with no effect in the Arc. To this author’s
knowledge, this is the first study to investigate the effects of betahistine treatment on
H1 receptor binding density in the rat brain. These results suggest a regional
difference exists in the effects of betahistine on H1 receptors in the brain. Brain
regional differential effects have also been observed in studies of the effects of other
drugs on H1 receptor binding density. For example, recently, Hu et al. found that
1mg/kg/day simvastatin (a hypolipidemic drug) significantly decreased H1 receptor
binding in the primary motor cortex, VMH, caudate putamen, accumbens core and
prefrontal cortex. Simvastatin (10 mg/kg/day) increased H1 receptor density in the
medial amygdaloid nucleus, but had no significant effect in other examined regions
(Hu et al., In press). In the present study, a single dosage of 8 mg/kg/day betahistine
was used and an important subject of future study would be to identify the regional
effect of dosage on H1 receptor binding density in the brain.

Interestingly, betahistine has both H1 agonist and H3 receptor antagonist binding
profiles (Yoshida et al., 2000; Fossati et al., 2001). Therefore, it is possible that
interactions between H1 and H3 receptors differ in various brain regions, which may
contribute to the regional difference observed in the present study. Further study is
needed to investigate the mechanisms and possible functional relevance regarding
the regional differences of betahistine on H1 receptors.
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Unexpectedly, sole olanzapine treatment had no effect on H1 receptor binding
density in the VMH and Arc. Previously, Han et al. (2008) reported that olanzapine
treatment for 1 and 12 weeks significantly decreased H1 receptor mRNA expression
in the VMH and Arc, and H1 receptor binding in the VMH. It is interesting that the
current study was not able to replicate the previous report by Han et al (2008). One
major difference between this study and that of Han et al. is that the rats were fasted
overnight in the present study but not in Han’s experiment. Moreover, the drug wash
out time in this study was 24 hours, rather than the 48 hours in Han’s study. The
VMH and Arc are brain regions that play key roles in the regulation of food intake
(Schwartz et al., 2000). It is possible that overnight fasting induces a stronger hunger
signal, which may stimulate H1 receptor expression in these hypothalamic nuclei, and
may therefore make the olanzapine-induced decrease in H1 receptor binding
undetectable. Previously, reports have shown that short-term and chronic treatment
of antipsychotic drugs has different effects on other receptor systems, such as
serotonin 5-HT1A and acetylcholine muscarinic receptors (Terry Jr et al., 2006; Han
et al., 2008; Han et al., 2009). Therefore, it is also important to examine the effects of
olanzapine and/or betahistine on H1 receptors after chronic treatment.

Further studies are important in order to examine histamine H1 receptor mRNA
expression. Moreover, it may be of benefit to omit overnight fasting prior to
obtaining brain tissue which limited suitability of correlative analysis. This alteration
of the method used in the present study would demonstrate the effects of olanzapine
and betahistine on H1 receptor expression in a non-fasting state.
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5.5 Summary
In summary, the present study identified a trend for betahistine to increase H1
receptor binding density in the VMH and significantly decrease H1 binding in the
DVC, which are important regulators of food intake and weight gain. However, this
study showed that sole olanzapine treatment had no effect on H1 receptor binding
density in the VMH, Arc and DVC, compared to controls. Examination of histamine
H1 receptor mRNA expression in the brain regions following betahistine and
olanzapine treatment is important for future studies. In addition, a chronic treatment
period, non-fasting conditions and different drug dosage could be applied to further
investigate the mechanism of betahistine and olanzapine on H1 receptors.
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CHAPTER 6
CONCLUSIONS, OVERALL DISCUSSION AND FUTURE
DIRECTIONS
6.1 Overall conclusion
Second-generation antipsychotic drugs have improved the treatment of schizophrenia
symptoms with fewer extra-pyramidal side effects. However, body weight
gain/obesity is a notable side effect of some atypical antipsychotics such as clozapine
and olanzapine (Allison et al., 1999; Allison and Casey, 2001). Furthermore, more
serious implications such as metabolic cardiovascular disease, patient compliance
and morbidity could follow this weight gain/obesity side effect. Although the exact
mechanism of atypical antipsychotic drugs, including olanzapine, in inducing body
weight gain side effects remains unknown, recent evidence indicates that the binding
affinities of these drugs to various neurotransmitter receptors, particularly histamine
H1 receptors, correlate with the weight gain/obesity side effect, and may even be
used to predict the likelihood of weight gain (Reynolds, 1997; Kroeze et al., 2003;
Matsui-Sakata et al., 2005). A series of experimental studies in animals and clinical
trials including behavioural and pharmacological treatments have been applied to
treat antipsychotic-induced weight gain/obesity side effects (Greenberg et al., 1999;
Allison and Casey, 2001; Khazaal et al., 2007). These trials were not based on H1
receptor antagonistic binding affinity as a predictor of antipsychotic-induced weight
gain/obesity, but were conducted largely according to empirical experience in the
clinic.
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•

We investigated the effect of betahistine in reducing olanzapine-induced
weight gain. This study investigated the effect of betahistine (an H1 receptor
agonist) in reducing olanzapine (an H1 receptor antagonist) -induced weight
gain in a rat model. Consistent with previous reports from both our laboratory
and other laboratories, olanzapine treatment substantially increases the body
weight of rats (+60% increase). Although betahistine treatment did not
influence body weight or food intake, co-treatment of betahistine with
olanzapine partially decreased olanzapine-induced body weight gain (-50%
decrease) (see more details in Chapter 3). Furthermore, food intake and
feeding efficiency were increased in rats treated with olanzapine, but feeding
efficiency was reduced by co-treatment. These results illustrate that
olanzapine can induce body weight gain, while co-treatment of olanzapine
and betahistine may be used to reduce the olanzapine-induced weight gain.

•

The role of locomotor activity proved important. Behavioural experiments
revealed that locomotor activity was decreased in both sole olanzapine and
co-treatment groups. In contrast, sole betahistine treatment had no effect on
locomotor activity. There was also no interaction between olanzapine and
betahistine. These results suggest that reduced activity partially contributed to
the weight gain side effect induced by olanzapine. Co-treatment with
betahistine did not improve locomotor activities decreased by olanzapine.
This finding may be one possible explanation of why betahistine can only
partially improve olanzapine-induced weight gain.
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•

The study showed that olanzapine can decrease insulin levels and O+B
co-treatment induced higher insulin levels than olanzapine. This hormone
measurement experiment has shown that olanzapine tended to decrease
fasting plasma insulin levels in rats. Interestingly, the O+B co-treatment of
olanzapine with betahistine can reverse the insulin level decreased by
olanzapine. No plasma PYY level change was detected among the different
drug groups in this study. Olanzapine and/or betahistine treatment had no
effect on fasting plasma PYY levels.

•

The first study to investigate the effects of betahistine treatment on
histamine H1 receptor binding density. This is the first study to investigate
the effects of betahistine treatment on histamine H1 receptor binding density
in the brain. Interestingly, we identified a brain regional response to
betahistine treatment. In other words, betahistine tended to increase H1
receptor binding density in the VMH, while significantly decreasing H1
receptor binding in the DVC, but had no effect in the Arc. As these regions
play significant roles in the regulation of food intake (Schwartz et al., 2000),
a regional difference in response to betahistine treatment may be related to
the regulation of food intake, although further experiments are necessary to
reveal exact functional relevance. It was unexpected that olanzapine lacked
effect on H1 receptor binding density in the regions analysed. As discussed in
Chapter 5, compared to a previous report (Han et al. 2008), overnight fasting
may affect H1 receptor expression. Another possible explanation is that
olanzapine may affect the binding affinity of H1 receptors, however this could
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not be revealed in an assay of a single concentration (10nM) of
[³H]pyrilamine (Tran et al., 1978). In further experiments to examine the
effects of olanzapine and/or betahistine on H1 receptors, an assay using
multiple concentrations of [³H]pyrilamine assay will be important.

6.2 General discussion and recommendations for future research
Based on the findings presented in this thesis, recommendations for further research
are listed below.
¾ Need for clinical trials indicated by results in rat model. The finding that cotreatment of olanzapine with betahistine can significantly reduce olanzapineinduced weight gain in the rat model provides an important clinical implication
for controlling the antipsychotic-induced weight/gain obesity side effect. Based
on our results, a clinical trial is recommended to test whether co-treatment of
olanzapine with betahistine is effective in controlling olanzapine-induced weight
gain in schizophrenia.

¾ Extension of co-treatment to other antipsychotics. Once proven effective in
olanzapine-treated schizophrenia patients, co-treatment of betahistine could be
extended to other antipsychotics with notable likelihood of weight gain/obesity.
As reviewed in Chapter 1, like olanzapine, clozapine, risperidone, and quetiapine
have strong or moderate weight gain side effects (Patel et al. 2009), which have
been correlated to their H1 receptor antagonist affinities (Kroeze et al., 2003;
Correll, 2008; Lian et al., 2010b). Therefore, it is valuable to trial how effectively
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the drug-induced weight gain side effect can be controlled through co-treatment
of olanzapine and betahistine.

¾ Need for increased physical activity in schizophrenia patients. Consistent
with previous reports in rats (Arjona et al., 2004; Weston-Green et al., 2010), this
study showed that reduced behavioural activity partially contributed to
olanzapine-induced weight gain. Several clinical studies have found that few
schizophrenia patients engage in vigorous physical exercise, particularly those
patients under olanzapine administration (Suzanne et al., 2007; Treuer et al.,
2009). This reduced activity of schizophrenia patients affects their energy
expenditure and contributes to high risks of body weight gain/obesity and other
metabolic side effects (Allison et al., 1999; Green et al., 2000). In this study,
betahistine did not improve locomotor activity reduced by olanzapine treatment,
which may account for the fact that it was only partially effective in improving
olanzapine-induced weight gain side effects. These results suggest that additional
physical activities are valuable when combining olanzapine therapy with
betahistine for a more effective control of weight gain/obesity side effects.

¾ Investigation of the time course of changes in insulin levels induced by
olanzapine, as well as the effects of chronic treatment of olanzapine on PYY
levels, needs to be undertaken. The result in this experiment was similar to the
acute olanzapine treatment studies in which using the same dosage in humans
and animals at dosages ranging from 0.75-6 mg/kg/day decreased fasting insulin
levels (Chiu et al., 2006; Chiu et al., 2010; Weston-Green et al., 2010).
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However, chronic olanzapine treatment increased plasma insulin levels (PerezIglesias et al., 2008; Wu et al., 2008). Therefore, further study is necessary to
discover the mechanisms of the time-course of insulin changes induced by
olanzapine. The O+B co-treatment of olanzapine and betahistine can reverse the
insulin decrease induced by olanzapine. Further binding experiments are
necessary to detect the cause. Although short-term treatment didn’t show any
difference in blood PYY levels, chronic olanzapine treatment requires further
investigation.

¾ Study of the effects of betahistine on different brain regions needed. Results
of this study have revealed that betahistine affects H1 receptor binding in a
regional difference pattern in the nuclei (DVC, VMH and Arc) relating to the
regulation of food intake and body weight. Reports have suggested the
involvement of the histamine H1 receptor in the pathophysiology of
schizophrenia (Nakai et al., 1991; Poyurovsky et al., 2005). Therefore, it is also
important to investigate whether betahistine has different effects in other brain
regions, particularly the areas related to the pathology of schizophrenia, such as
the prefrontal cortex and hippocampus (Brown et al., 2001).

¾ Other effects of betahistine need to be investigated. Although this study found
that betahistine could partially reduce olanzapine-induced weight gain, the
mechanisms underlying this action are not clear, for example, how betahistine
interacts with olanzapine in the hypothalamic and brainstem nuclei to regulate
food intake. In addition to H1 receptor binding, we should examine how
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betahistine affects mRNA expression of the H1 receptor. Furthermore, as
olanzapine can reduce thermogenesis in rats, contributing to body weight gain
(Stefanidis et al., 2008), it is also important to investigate whether betahistine
affects thermogenesis.

¾ Investigation of different dosages and testing periods may be of value. In this
study, only one dosage of olanzapine (3 mg/kg/day) and betahistine (8
mg/kg/day) were administered over the two weeks experimental period. Since
different dosages of drugs or testing periods may induce various effects, further
studies involving, other dosages and long-term drug treatment may be of
significant value.

¾ Injection of FMPH in hypothalamus of rats. Betahistine exhibits both H1
agonism and H3 antagonism properties. However, only its H1 agonistic effect was
studied in this project because no other highly selective and orally deliverable H1
agonist was available in the Australian market. Another selective H1 receptor
agonist is 2-(3-trifluoromethylphenyl)histamine (FMPH), which is unable to
cross the blood brain barrier. Injecting FMPH into the hypothalamus of rats may
prove necessary to detect the effect of the H1 receptor on the key brain region.

Conclusion
In conclusion, this project has shown that olanzapine can induce body weight gain in
rats, resulting from increased food intake and feeding efficiency, and decreased
locomotor activity. Co-treatment of betahistine with olanzapine can partially improve
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olanzapine-induced weight gain side effect through reduced feed efficiency and food
intake. Although the pharmacological mechanisms still require further investigation,
this study confirmed our hypothesis that the use of a H1 receptor agonist can improve
antipsychotic-induced weight gain/obesity side effects. These findings have
important implications for clinical trials using betahistine to improve olanzapine
induced weight gain/obesity side effects obesity.
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